1
|
Judkins J, Moore B, Stone E, Welsh A, Carbon G, Rendell B, Peterson A. Pilot investigation of an activity-based approach to building hardiness. BMJ Mil Health 2023; 169:350-354. [PMID: 34413115 DOI: 10.1136/bmjmilitary-2020-001661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Accepted: 08/13/2021] [Indexed: 11/03/2022]
Abstract
BACKGROUND The purpose was to describe an activity-based psychological hardiness training programme delivered by an occupational therapist and examine its acceptability and effectiveness in improving hardiness. METHOD Participants (N=28) completed the 6-hour programme, which included pre/post-programme completion of the Dispositional Resilience Scale-15 (DRS-15) and a Program Evaluation Form. Paired t-tests were used to determine differences between pre-training and post-training scores on the DRS-15. RESULTS Results showed a significant increase (p<0.05) in total hardiness, commitment, and control scores on the DRS-15 from pre-training to post-training and good-excellent ratings for all categories on the Program Evaluation Form. CONCLUSIONS This programme evaluation described an occupational therapist's role in providing an activity-based psychological hardiness training programme and provided preliminary support for the acceptability of an activity-based approach to training psychological hardiness for service members.
Collapse
Affiliation(s)
- Jason Judkins
- Military Performance Department, US Army Research Institute of Environmental Medicine, Natick, Massachusetts, USA
| | - B Moore
- Department of Psychological Science, Kennesaw State University, Kennesaw, Georgia, USA
| | - E Stone
- 5-20 Infantry Battalion, 1-2 Stryker Brigade Combat Team, Joint Base Lewis-McChord, Washington, USA
| | - A Welsh
- US Army Institute of Surgical Research, Fort Sam Houston, Texas, USA
| | - G Carbon
- Center for Army Analysis, Fort Belvior, Virginia, USA
| | - B Rendell
- AFROTC Detachment 842, University of Texas at San Antonio, San Antonio, Texas, USA
| | - A Peterson
- Department of Psychiatry & Behavioral Sciences, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
| |
Collapse
|
2
|
Peck ME, Ong K, Lucas T, Thomas AG, Wandira R, Ntwaaga B, Mkhontfo M, Zegeye T, Yohannes F, Mulatu D, Gultie T, Juma AW, Odoyo-June E, Maida A, Msungama W, Canda M, Mutandi G, Zemburuka BLT, Kankindi I, Vranken P, Maphothi N, Loykissoonlal D, Bunga S, Grund JM, Kazaura KJ, Kabuye G, Chituwo O, Muyunda B, Kamboyi R, Lingenda G, Mandisarisa J, Peterson A, Malaba R, Xaba S, Moyo T, Toledo C. Preventing HIV Among Adolescent Boys and Young Men Through PEPFAR-Supported Voluntary Medical Male Circumcision in 15 Sub-Saharan African Countries, 2018-2021. AIDS Educ Prev 2023; 35:67-81. [PMID: 37406146 PMCID: PMC11002756 DOI: 10.1521/aeap.2023.35.suppa.67] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/07/2023]
Abstract
Voluntary medical male circumcision (VMMC) is an HIV prevention intervention that has predominantly targeted adolescent and young men, aged 10-24 years. In 2020, the age eligibility for VMMC shifted from 10 to 15 years of age. This report describes the VMMC client age distribution from 2018 to 2021, at the site, national, and regional levels, among 15 countries in southern and eastern Africa. Overall, in 2018 and 2019, the highest proportion of VMMCs were performed among 10-14-year-olds (45.6% and 41.2%, respectively). In 2020 and 2021, the 15-19-year age group accounted for the highest proportion (37.2% and 50.4%, respectively) of VMMCs performed across all age groups. Similarly, in 2021 at the site level, 68.1% of VMMC sites conducted the majority of circumcisions among men aged 15-24 years. This analysis highlights that adolescent boys and young men are the primary recipients of VMMC receiving an important lifetime reduction in HIV risk.
Collapse
Affiliation(s)
- Megan E Peck
- Division of Global HIV and Tuberculosis (TB), Center for Global Health (CGH), Centers for Disease Control and Prevention (CDC), Atlanta, Georgia
| | - Katherine Ong
- Division of Global HIV and Tuberculosis (TB), Center for Global Health (CGH), Centers for Disease Control and Prevention (CDC), Atlanta, Georgia
| | - Todd Lucas
- Division of Global HIV and Tuberculosis (TB), Center for Global Health (CGH), Centers for Disease Control and Prevention (CDC), Atlanta, Georgia
| | - Anne G Thomas
- HIV/AIDS Prevention Program, U.S. Department of Defense, San Diego, California
| | - Ronald Wandira
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | | | - Mandzisi Mkhontfo
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | - Tiruneh Zegeye
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | - Fikirte Yohannes
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | - Dejene Mulatu
- Disease Prevention and Control Directorate Senior, HIV Prevention and Control Expert, Addis Ababa, Ethiopia
| | | | | | - Elijah Odoyo-June
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | - Alice Maida
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | - Wezi Msungama
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | - Marcos Canda
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | - Gram Mutandi
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | - Brigitte L T Zemburuka
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | - Ida Kankindi
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | - Peter Vranken
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | - Nandi Maphothi
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | | | - Sudhir Bunga
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | - Jonathan M Grund
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | - Kokuhumbya J Kazaura
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | - Geoffrey Kabuye
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | - Omega Chituwo
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | - Brian Muyunda
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | | | | | - John Mandisarisa
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | - Amy Peterson
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | - Rickie Malaba
- The following authors are affiliated with the respective country offices of the Division of Global HIV and TB, CGH, CDC: Ronald Wandira (Gaborone, Botswana), Mandzisi Mkhontfo (Mbabane, Eswatini), Tiruneh Zegeye, and Fikirte Yohannes (Addis Ababa, Ethiopia), Elijah Odoyo-June (Nairobi, Kenya), Alice Maida, and Wezi Msungama (Lilongwe, Malawi), Marcos Canda (Maputo, Mozambique), Gram Mutandi, and Brigitte L. T. Zemburuka (Windhoek, Namibia), Ida Kankindi (Kigali, Rwanda), Peter Vranken, and Nandi Maphothi (Pretoria, South Africa), Sudhir Bunga (Juba, South Sudan), Jonathan M. Grund, and Kokuhumbya J. Kazaura (Dar es Salaam, Tanzania), Geoffrey Kabuye (Kampala, Uganda), Omega Chituwo, and Brian Muyunda (Lusaka, Zambia), and John Mandisarisa, Amy Peterson, and Rickie Malaba (Harare, Zimbabwe)
| | | | - Talent Moyo
- Ministry of Health and Child Care, Harare, Zimbabwe
| | - Carlos Toledo
- Division of Global HIV and Tuberculosis (TB), Center for Global Health (CGH), Centers for Disease Control and Prevention (CDC), Atlanta, Georgia
| |
Collapse
|
3
|
Matsubayashi H, Mountain J, Yao T, Peterson A, Roy AD, Inoue T. Non-catalytic role of phosphoinositide 3-kinase in mesenchymal cell migration through non-canonical induction of p85β/AP-2-mediated endocytosis. Res Sq 2023:rs.3.rs-2432041. [PMID: 36712095 PMCID: PMC9882665 DOI: 10.21203/rs.3.rs-2432041/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Class IA phosphoinositide 3-kinase (PI3K) galvanizes fundamental cellular processes such as migration, proliferation, and differentiation. To enable multifaceted roles, the catalytic subunit p110 utilizes a multi-domain, regulatory subunit p85 through its inter SH2 domain (iSH2). In cell migration, their product PI(3,4,5)P3 generates locomotive activity. While non-catalytic roles are also implicated, underlying mechanisms and its relationship to PI(3,4,5)P3 signaling remain elusive. Here, we report that a disordered region of iSH2 contains previously uncharacterized AP-2 binding motifs which can trigger clathrin and dynamin-mediated endocytosis independent of PI3K catalytic activity. The AP-2 binding motif mutants of p85 aberrantly accumulate at focal adhesions and upregulate both velocity and persistency in fibroblast migration. We thus propose the dual functionality of PI3K in the control of cell motility, catalytic and non-catalytic, arising distinctly from juxtaposed regions within iSH2.
Collapse
|
4
|
Mankovich N, Kehoe E, Peterson A, Kirby M. Pathway expression analysis. Sci Rep 2022; 12:21839. [PMID: 36528702 PMCID: PMC9759056 DOI: 10.1038/s41598-022-26381-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2022] [Accepted: 12/14/2022] [Indexed: 12/23/2022] Open
Abstract
This paper introduces a pathway expression framework as an approach for constructing derived biomarkers. The pathway expression framework incorporates the biological connections of genes leading to a biologically relevant model. Using this framework, we distinguish between shedding subjects post-infection and all subjects pre-infection in human blood transcriptomic samples challenged with various respiratory viruses: H1N1, H3N2, HRV (Human Rhinoviruses), and RSV (Respiratory Syncytial Virus). Additionally, pathway expression data is used for selecting discriminatory pathways from these experiments. The classification results and selected pathways are benchmarked against standard gene expression based classification and pathway ranking methodologies. We find that using the pathway expression data along with selected pathways, which have minimal overlap with high ranking pathways found by traditional methods, improves classification rates across experiments.
Collapse
Affiliation(s)
- Nathan Mankovich
- grid.47894.360000 0004 1936 8083Colorado State University, Mathematics, Fort Collins, 80523 USA
| | - Eric Kehoe
- grid.47894.360000 0004 1936 8083Colorado State University, Mathematics, Fort Collins, 80523 USA
| | - Amy Peterson
- grid.47894.360000 0004 1936 8083Colorado State University, Mathematics, Fort Collins, 80523 USA
| | - Michael Kirby
- grid.47894.360000 0004 1936 8083Colorado State University, Mathematics, Fort Collins, 80523 USA
| |
Collapse
|
5
|
Singh N, Peterson A, Baraff A, Chung S, Bhatti P, Coffey D, Barton J, LI C, Smith N, Weiss N. POS1422 USE OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS AND RISK OF MULTIPLE MYELOMA IN PERSONS WITH RHEUMATOID ARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundBiologic therapies used in the management of rheumatoid arthritis (RA) target several cytokines that have been implicated in the pathogenesis of multiple myeloma (MM). Yet little is known about the association between use of biologic or targeted synthetic disease modifying anti-rheumatic drugs (b or tsDMARDs) in RA and the incidence of MM.ObjectivesOur objective was to estimate the association between b/tsDMARD use and the risk of MM among persons with RA using Veterans Health Administration (VHA) data. We hypothesized that b-/tsDMARD use is associated with a lower incidence of MM compared with conventional synthetic DMARDs (csDMARDs).MethodsIn this retrospective cohort study, we identified patients >18 years of age diagnosed with RA in any United States VHA facility from 1/1/2002 and 12/31/2018. All patients met the following inclusion criteria: 1) two or more International Classification of Diseases Version 9 or 10 (ICD9 or ICD10) codes for RA at least 7 days apart but no more than 365 days apart 2) a prescription for a csDMARD within 90 days of the first RA diagnosis 3) one inpatient or outpatient visit 30 days to 2 years preceding first RA diagnosis (indicating a regular user of VHA). Medication data was derived from the outpatient prescription fills, bar coded medication administration (BCMA), and intravenous (IV) data domains. The csDMARDs included in these analyses were: methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine. The bDMARDs included were tumor necrosis factor inhibitors (TNFi) and non-TNFi biologics such as tocilizumab, rituximab, abatacept, and biosimilars; tsDMARD was tofacitinib. Patients with MM before the diagnosis of RA were excluded. Incident MM was determined by 1 or more ICD9/10 code or ICD-oncology codes. Multivariable Cox proportional hazards model were performed to estimate the hazard ratio for developing MM among those during and following the use of a b-/tsDMARD relative to b-/tsDMARD-naïve persons adjusting for age, gender, race, and ethnicity.Results27,540 veterans with RA met study eligibility criteria, of whom 8,322 (30%) had taken a b-/tsDMARD. Over the study period there were 77 incident MM over a total of 192,000 person years. There were 55 events in users of csDMARDs, an incidence rate (IR) of 0.40 (95% CI 0.30-0.52) per 1000 person-years and 22 in persons currently or formerly using b-/tsDMARDs (IR 0.41, 0.25-0.61 per 1000 person years). The unadjusted hazard ratio for MM following bDMARD use relative to csDMARD only use was 1.04 (0.63, 1.73), which increased to 1.28 (0.76, 2.16) after adjusting for demographic characteristics (Table 1).Table 1.Multivariable Cox proportional hazards model for association between use of disease modifying anti-rheumatic drugs and incident multiple myeloma.Clinical characteristicHazards ratio (95% CI)csDMARDReferenceb-/tsDMARD use1.28 (0.76-2.16)Age*1.04 (1.02-1.07)Female0.58 (0.20-1.62)RaceReferenceWhite2.11 (1.15-3.86)Black0.70 (0.10-5.08)OtherHispanic Ethnicity0.71 (0.17-2.92)Abbreviations: b-/tsDMARD- biologic or targeted synthetic disease modifying anti-rheumatic drug; CI: confidence interval*Hazards ratio reflects risk per every 1-year increase in ageModel adjusted for age, gender, race, and ethnicityConclusionIn this nationwide VA study, we did not observe an association between bDMARD use and the incidence of MM. Of note, the median interval from initiation of a bDMARD to the end of follow-up was approximately 5.8 years, which does not allow for an examination of a possible longer term influence.Disclosure of InterestsNone declared
Collapse
|
6
|
Singh N, Peterson A, Baraff A, Bhatti P, Gopal A, Smith N, Barton J, Curtis J, LI C, Weiss N. POS1434 USE OF BIOLOGIC OR TARGETED SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS AND THE RISK OF LYMPHOMA IN RHEUMATOID ARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundEpidemiologic studies suggest that disease duration and degree of inflammatory activity of rheumatoid arthritis (RA) contribute to lymphoma development (1). Whether the decrease in inflammatory burden seen with use of biologic or targeted synthetic disease modifying anti-rheumatic drugs (bDMARDs or tsDMARDs) translates into a lower risk of lymphoma in RA needs to be studied.ObjectivesThe objective of our study was to examine the effect of administration of b/tsDMARDS on the incidence of lymphoma relative to conventional synthetic DMARDs (csDMARDs) in an inception cohort of Veterans with RA.MethodsWe identified patients >18 years of age diagnosed with RA in any US Veterans Affairs (VA) facility from 1/1/2002 and 12/31/2018 using the VA Corporate Data Warehouse (CDW). To be included, each patient was required to meet the following criteria: 2+ RA diagnostic codes at least 7 days apart but no more than 365 days apart; 2) a prescription for a csDMARD within 90 days of the first RA diagnosis; and 3) an inpatient or outpatient visit 30 days to 2 years preceding first RA diagnosis (indicating they are a regular user of the VA). The csDMARDs included in these analyses were: methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine. The bDMARDs included were tumor necrosis factor inhibitors (TNFi) and non-TNFi biologics such as tocilizumab, rituximab, abatacept, and biosimilars; tsDMARD was tofacitinib. Patients with prevalent lymphoma were excluded. Lymphoma diagnoses were identified using International Classification of Diseases Version 9, 10 and Oncology (ICD9, ICD10, ICDO) codes.We used marginal structural models as described by Hernan et al (2) and time-varying Cox models to control for confounding by indication while evaluating this association. We adjusted for baseline demographics (age, sex, race, ethnicity, year of cohort entry, rheumatology visits), and time-varying CRP and time-varying Rheumatoid Disease Comorbidity Index (RDCI) (3) to control for confounding.Results27,421 Veterans with RA met our eligibility criteria. Most of the Veterans (56%) were in the age range 61-80 years old; 89% male, 76% White, 14% African American. 8,225 (30%) patients were treated with a b-/tsDMARD. The crude incidence rates were 1.71 (95% CI 1.5-1.94) per 1000 person-years for those only on csDMARDs and 1.78 (95% CI 1.44-2.18) for patients during or following use of a b/tsDMARDs. After adjustment with both time-fixed and time-varying covariates using marginal structural models, the incidence of lymphoma was not different between patients who did and did not use a b/tsDMARD (hazard ratio=1.06, 95% CI= 0.82-1.37) (Table 1).Table 1.Estimates of Effect of bDMARD or tsDMARD use on Lymphoma relative to use of csDMARDsMarginal Structural Models; adjusted for:@Demographics1.04(0.80, 1.34)#Demographics + CRP1.06(0.82, 1.37)* per 1000 person-years@Demographics = age, gender, race, ethnicity, rheumatology visits, and year of cohort entry#Adjusts for CRP, baseline rheumatology visits (yes/no) and RDCI.CRP = C-Reactive Protein, RDCI = Rhematic Disease Comorbidity Index, CI = Confidence Interval, b/tsDMARD = biologic or targeted synthetic DMARD, csDMARD = conventional synthetic DMARDConclusionIn this large study using the nationwide VA data, we did not observe an association between the use of b/ts DMARDs and an increased risk of lymphoma.References[1]Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692-701.[2]Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550-60.[3]England BR, Sayles H, Mikuls TR, Johnson DS, Michaud K. Validation of the rheumatic disease comorbidity index. Arthritis care & research. 2015;67(6):865-72.Disclosure of InterestsNone declared
Collapse
|
7
|
Zhang X, DeSantes K, Dodge A, Larson M, Eickhoff J, Moreno M, Peterson A. Practices and Attitudes Regarding Pediatric Cholesterol Screening Recommendations Differ Between Pediatricians and Family Medicine Clinicians. Pediatr Cardiol 2022; 43:631-635. [PMID: 34727231 DOI: 10.1007/s00246-021-02767-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Accepted: 10/26/2021] [Indexed: 11/30/2022]
Abstract
Pediatricians had higher rates of ordering pediatric cholesterol screening than family medicine (FM) clinicians. This study aims to compare knowledge, attitude, and practices of clinicians' pediatric cholesterol screening practices and attitudes between these two specialties. A 14-item electronic survey using Likert scales was sent to all clinicians in the institution's Departments of Pediatrics and FM between 2018 and 2019. Chi-square and t-tests were used to compare pediatricians and FM clinicians. 22 clinicians from Pediatrics and 111 from FM completed the survey. Compared to FM clinicians, pediatricians were more familiar with the National Heart, Lung, and Blood Institute guidelines, which are more vigorous in their recommendation of universal cholesterol screening. Pediatricians reported being more supportive of universal cholesterol screening in children (p < 0.05). In practice, pediatricians reported screening almost two thirds (64.8%) of eligible patients during the past year, while FM clinicians reported screening approximately one third (34.1%) of eligible patients (p < 0.001). Pediatricians were more likely to screen based on patient-specific risk factors and their practice decisions were more heavily influenced by published guidelines, institutional education, availability of non-fasting blood to be used for screening, and the availability of an institutional pediatric lipid clinic (p < 0.05). The differences in knowledge, attitudes, and practices of cholesterol screening may contribute to different screening rates among clinicians from FM and pediatrics. To improve patient care and reduce gaps, it is important to implement interventions at the institutional level as well as to adopt uniform guideline recommendations at the national level.
Collapse
Affiliation(s)
- Xiao Zhang
- Department of Pediatrics, Division of Pediatric Cardiology, University of Wisconsin School of Medicine and Public Health, CSC H6/534 MC 4108, 600 Highland Ave., Madison, WI, 53792, USA.
| | - Kathleen DeSantes
- Department of Pediatrics, Division of General Pediatrics and Adolescent Medicine, University of Wisconsin School of Medicine and Public Health, 2870 University Ave. Ste. 200 MC 9010, Madison, WI, 53705, USA
| | - Ann Dodge
- Department of Pediatrics, Division of Pediatric Cardiology, University of Wisconsin School of Medicine and Public Health, CSC H6/534 MC 4108, 600 Highland Ave., Madison, WI, 53792, USA
| | - Magnolia Larson
- Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, 100 North Nine Mound Road, Verona, WI, 53593, USA
| | - Jens Eickhoff
- Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, 207 J WARF, 610 Walnut Street, Madison, WI, 53726, USA
| | - Megan Moreno
- Department of Pediatrics, Division of General Pediatrics and Adolescent Medicine, University of Wisconsin School of Medicine and Public Health, 2870 University Ave. Ste. 200 MC 9010, Madison, WI, 53705, USA
| | - Amy Peterson
- Department of Pediatrics, Division of Pediatric Cardiology, University of Wisconsin School of Medicine and Public Health, CSC H6/534 MC 4108, 600 Highland Ave., Madison, WI, 53792, USA
| |
Collapse
|
8
|
Held PK, Campbell K, Wiberley-Bradford AE, Lasarev M, Horner V, Peterson A. Analytical Validation of Familial Hypercholesterolemia Biomarkers in Dried Blood Spots. Int J Neonatal Screen 2022; 8:ijns8010014. [PMID: 35225936 PMCID: PMC8883967 DOI: 10.3390/ijns8010014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/28/2021] [Revised: 02/01/2022] [Accepted: 02/05/2022] [Indexed: 12/07/2022] Open
Abstract
Heterozygous familial hypercholesterolemia (HeFH) is a common, treatable genetic disorder characterized by premature atherosclerosis and cardiovascular disease, yet the majority of affected individuals remain undiagnosed. Newborn screening could play a role in identification of at-risk individuals and provide an opportunity for early intervention, prior to the onset of symptoms. The objective of this study was to develop and validate assays for quantification of candidate HeFH biomarkers in dried blood spots (DBS). Commercially available enzyme assay kits for quantification of serum total cholesterol (TC) and low-density lipoprotein-cholesterol (LDL-C) were modified for high-throughput analysis of DBS. Apolipoprotein B (ApoB) concentrations in DBS were measured using an immunoassay with modifications from published studies. All three assays were validated according to the College of American Pathologists guidelines for clinical laboratories. The performance of TC, LDL-C, and ApoB assays was assessed by precision, recovery, limit of quantification (LOQ) and linearity. Precision studies yielded coefficients of variation (CV) of less than 15%, with recovery greater than 75% for all three assays. The determined LOQ and linearity were comparable to serum-based assays. In a direct comparison between serum and DBS concentrations, positive correlations were demonstrated for TC, LDL-C, and ApoB. Additionally, the initial evaluation of the three biomarker concentrations within the unaffected population was similar to values obtained in previous published studies. This study reports on methods for quantification of TC, LDL-C, and ApoB in DBS. Assay validation results were within acceptable limits for newborn screening. This is an important first step toward the identification of newborns with HeFH.
Collapse
Affiliation(s)
- Patrice K. Held
- Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53706, USA;
- Wisconsin State Laboratory of Hygiene, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53706, USA; (K.C.); (A.E.W.-B.)
- Correspondence: ; Tel.: +1-608-265-5968
| | - Kristin Campbell
- Wisconsin State Laboratory of Hygiene, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53706, USA; (K.C.); (A.E.W.-B.)
| | - Amy E. Wiberley-Bradford
- Wisconsin State Laboratory of Hygiene, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53706, USA; (K.C.); (A.E.W.-B.)
| | - Michael Lasarev
- Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53706, USA;
| | - Vanessa Horner
- Department of Pathology, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53706, USA;
| | - Amy Peterson
- Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53706, USA;
| |
Collapse
|
9
|
Diesel J, Peterson A, Peterman T. Reported Chlamydia and Gonorrhea Are Decreasing Among Young Black Women: Good News or Bad News? A Narrative Review. Sex Transm Dis 2021; 48:e228-e235. [PMID: 34091582 PMCID: PMC10308433 DOI: 10.1097/olq.0000000000001491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
ABSTRACT Since 2010, reported chlamydia and gonorrhea rates decreased among Black women aged 15 to 19 years and were stable for Black women aged 20 to 24 years in the United States. Rates increased for older Black women aged 25 to 39 years and all White women. The Black/White rate ratio decreased across age groups. We examined whether trends in reported rates reflected changing prevalence or changing screening. We analyzed trends in reported chlamydia and gonorrhea rates from 2010 to 2018 among women in the United States aged 15 to 39 years by age and race/ethnicity subgroup, state, and reporting source. Most jurisdictions reported decreased chlamydia and gonorrhea rates among Black teens and increased rates among White teens and older women. Between 2010 and 2018, public clinics reported fewer cases, especially among young Black women, that were not restored by increases elsewhere. We reviewed literature on trends in screening, prevalence, and sequelae. Family planning clinics annual reports showed chlamydia tests among women younger than 25 years decreased by 541,573 tests (-38%) in 2018 compared with 2010 and the number of women visiting sexually transmitted disease clinics had decreased 50% by 2016 compared with 2010. Prevalence of chlamydia in a sentinel population (Job Corps) was unchanged for Black women younger than 25 years and increased for Whites aged 20 to 24 years. Sequelae trends using data from a large all-payer emergency department database were mixed: pelvic inflammatory disease decreased, whereas ectopic pregnancy increased. Decreases in testing at public clinics likely missed diagnoses among young Black women, a group traditionally at highest risk and in need of more testing. Innovative approaches to screening are needed.
Collapse
Affiliation(s)
- Jill Diesel
- Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of STD Prevention, Atlanta, GA
- Michigan Department of Health and Human Services, Detroit, MI
| | - Amy Peterson
- Michigan Department of Health and Human Services, Detroit, MI
| | - Thomas Peterman
- Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of STD Prevention, Atlanta, GA
| |
Collapse
|
10
|
Wang LY, Peterson A, Li J, Coleman K, Dunville R. Cost-Effectiveness Analysis of Michigan's School-Wide Sexually Transmitted Disease Screening Program in Four Detroit High Schools. J Adolesc Health 2021; 69:957-963. [PMID: 34289955 PMCID: PMC9281505 DOI: 10.1016/j.jadohealth.2021.05.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Revised: 04/26/2021] [Accepted: 05/18/2021] [Indexed: 11/29/2022]
Abstract
PURPOSE The Michigan Department of Health and Human Services, in collaboration with St. John Providence Health System, initiated voluntary school-wide sexually transmitted disease (STD) screenings in four Detroit public high schools. We sought to assess the cost-effectiveness of the STD screening program from 2010 to 2015, with a focus on chlamydia. METHODS The costs and effectiveness of the school-based screening were compared with those of a "no school screening" scenario using a healthcare system perspective. A decision tree model was constructed to project cases of chlamydia, epididymitis, and pelvic inflammatory disease (PID) in each of the two scenarios among students tested positive and their partners. Health effects were measured as cases of PID prevented, and quality-adjusted life-years (QALYs) gained. Cost estimates included program costs, chlamydia testing/treatment costs in the absence of school screening, and treatment costs for epididymitis, PID, and PID sequelae. The incremental cost-effectiveness ratio (ICER) was measured as cost/QALY gained. Multivariate sensitivity analyses were conducted on key parameter estimates and assumptions used. RESULTS Under base-case assumptions, at a total program cost of $333,848 over 5 years, the program prevented an estimated 1.9 cases of epididymitis and 17.3 cases of PID, resulting in an ICER of $38,235/QALY gained (yearly ICER ranging from $27,417 to $50,945/QALY). Of 10,000 Monte Carlo simulation runs, the yearly ICER remained ≤$50,000/QALY in 64%-98% of the simulation runs. CONCLUSIONS We found favorable cost-effectiveness ratios for Michigan's school-wide STD screening program in Detroit. School-based STD screening programs of this type warrant careful considerations by policy makers and program planners.
Collapse
Affiliation(s)
- Li Yan Wang
- Division of Adolescent and School Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
| | - Amy Peterson
- Division of HIV and STD Programs, Michigan Department of Health and Human Services, Detroit, Michigan
| | - Jingjing Li
- Division of Adolescent and School Health, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Kenneth Coleman
- Ascension Southeast Michigan Community Health, Detroit, Michigan
| | - Richard Dunville
- Division of Adolescent and School Health, Centers for Disease Control and Prevention, Atlanta, Georgia
| |
Collapse
|
11
|
Abstract
In this article, we describe a science- and justice-based framework for promoting health equity designed for researchers and practitioners working across public health and social science fields. We developed the health equity framework (HEF; etr.org/healthequityframework) in two phases of iterative development. Building on existing models, the HEF illustrates how health outcomes are influenced by complex interactions between people and their environments. The framework centers on three foundational concepts: equity at the core of health outcomes; multiple, interacting spheres of influence; and a historical and life-course perspective. Health equity is defined as having the personal agency and fair access to resources and opportunities needed to achieve the best possible physical, emotional, and social well-being. By centering population outcomes, the HEF encourages researchers and practitioners to think beyond traditional approaches that focus on individual behaviors and choices to assess and identify their gaps in acknowledging and addressing factors from multiple spheres of influence. We identified four, interacting spheres of influence that represent both categories of risk and protective factors for health outcomes as well as opportunities for strategies and interventions that address those factors. The HEF highlights the explicit and implicit interactions of multilevel influences on health outcomes and emphasizes that health inequities are the result of cumulative experiences across the life span and generations. The HEF is a practical tool for leaders and professionals in public health research and practice to reflect on and support a shift toward addressing health inequities resulting from the interplay of structural, relational, individual, and physiological factors.
Collapse
|
12
|
Block RC, Bang M, Peterson A, Wong ND, Karalis DG. Awareness, diagnosis and treatment of heterozygous familial hypercholesterolemia (HeFH) - Results of a US national survey. J Clin Lipidol 2021; 15:682-689. [PMID: 34593357 DOI: 10.1016/j.jacl.2021.09.045] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Revised: 08/09/2021] [Accepted: 09/08/2021] [Indexed: 11/16/2022]
Abstract
BACKGROUND HeFH is a common inherited disorder that leads to markedly elevated LDL-cholesterol from birth and premature cardiovascular disease. HeFH is frequently underdiagnosed and undertreated. OBJECTIVE To compare how well primary care physicians and cardiologists recognize and treat HeFH. METHODS The National Lipid Association surveyed 500 primary care physicians and 500 cardiologists in the US who have patients with baseline LDL-cholesterol ≥ 190 mg/dL. The survey was conducted between August 29 and September 30, 2019. RESULTS For a hypothetical case of HeFH, 57% of cardiologists versus 43% of primary care physicians made the correct diagnosis (P<0.001). Among respondents, 21% of cardiologists versus 29% of primary care physicians have never made a diagnosis of HeFH in a patient with an LDL-cholesterol ≥ 190 mg/dL (P<0.004). Only 7% of cardiologists versus 5% of primary care physicians would refer to a lipid specialist (P=0.05). For additional LDL-cholesterol lowering after statins, 58% of cardiologists versus 48% of primary care physicians would prescribe a PCSK9 inhibitor (P=0.004); however, 30% of cardiologists versus 53% of primary care physicians have never prescribed a PSCK9 inhibitor in an HeFH patient (P<0.001). CONCLUSION Although cardiologists compared to primary care physicians are somewhat more likely to recognize and treat HeFH patients according to guidelines, both physician specialties do not adequately recognize or treat HeFH. There is a need for more education and training in recognizing and treating HeFH, greater access to lipid specialists, and fewer barriers for PCSK9 inhibitor use.
Collapse
Affiliation(s)
- Robert C Block
- Cardiology Division, University of Rochester Medical Center, Rochester, NY 14623, United States (Block)
| | - Matthew Bang
- Heart Disease Prevention Program, Division of Cardiology, School of Medicine, University of California Irvine, Irvine, CA 92697, United States (Bang, Wong)
| | - Amy Peterson
- Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, United States (Peterson)
| | - Nathan D Wong
- Heart Disease Prevention Program, Division of Cardiology, School of Medicine, University of California Irvine, Irvine, CA 92697, United States (Bang, Wong)
| | - Dean G Karalis
- Department of Cardiology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, United States (Karalis).
| |
Collapse
|
13
|
Aminian M, Ghosh T, Peterson A, Rasmussen AL, Stiverson S, Sharma K, Kirby M. Early prognosis of respiratory virus shedding in humans. Sci Rep 2021; 11:17193. [PMID: 34433834 PMCID: PMC8387366 DOI: 10.1038/s41598-021-95293-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2020] [Accepted: 07/23/2021] [Indexed: 11/24/2022] Open
Abstract
This paper addresses the development of predictive models for distinguishing pre-symptomatic infections from uninfected individuals. Our machine learning experiments are conducted on publicly available challenge studies that collected whole-blood transcriptomics data from individuals infected with HRV, RSV, H1N1, and H3N2. We address the problem of identifying discriminatory biomarkers between controls and eventual shedders in the first 32 h post-infection. Our exploratory analysis shows that the most discriminatory biomarkers exhibit a strong dependence on time over the course of the human response to infection. We visualize the feature sets to provide evidence of the rapid evolution of the gene expression profiles. To quantify this observation, we partition the data in the first 32 h into four equal time windows of 8 h each and identify all discriminatory biomarkers using sparsity-promoting classifiers and Iterated Feature Removal. We then perform a comparative machine learning classification analysis using linear support vector machines, artificial neural networks and Centroid-Encoder. We present a range of experiments on different groupings of the diseases to demonstrate the robustness of the resulting models.
Collapse
Affiliation(s)
- M Aminian
- Department of Mathematics and Statistics, California State Polytechnic University, Pomona, CA, USA
| | - T Ghosh
- Department of Computer Science, Colorado State University, Fort Collins, CO, 80524, USA
| | - A Peterson
- Department of Mathematics, Colorado State University, Fort Collins, CO, 80524, USA
| | - A L Rasmussen
- Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac), University of Saskatchewan, Saskatoon, SK, Canada.,Center for Global Health Science and Security, Georgetown University Medical Center, Washington, DC, USA
| | - S Stiverson
- Department of Mathematics, Colorado State University, Fort Collins, CO, 80524, USA
| | - K Sharma
- Department of Computer Science, Colorado State University, Fort Collins, CO, 80524, USA
| | - M Kirby
- Department of Mathematics, Colorado State University, Fort Collins, CO, 80524, USA. .,Department of Computer Science, Colorado State University, Fort Collins, CO, 80524, USA.
| |
Collapse
|
14
|
Ding EY, Erskine N, Stut W, McManus DD, Peterson A, Wang Z, Escobar Valle J, Albuquerque D, Alonso A, Botkin NF, Pack QR, McManus DD. MI-PACE Home-Based Cardiac Telerehabilitation Program for Heart Attack Survivors: Usability Study. JMIR Hum Factors 2021; 8:e18130. [PMID: 34255660 PMCID: PMC8299347 DOI: 10.2196/18130] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2020] [Revised: 05/17/2020] [Accepted: 03/18/2021] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Cardiac rehabilitation programs, consisting of exercise training and disease management interventions, reduce morbidity and mortality after acute myocardial infarction. OBJECTIVE In this pilot study, we aimed to developed and assess the feasibility of delivering a health watch-informed 12-week cardiac telerehabilitation program to acute myocardial infarction survivors who declined to participate in center-based cardiac rehabilitation. METHODS We enrolled patients hospitalized after acute myocardial infarction at an academic medical center who were eligible for but declined to participate in center-based cardiac rehabilitation. Each participant underwent a baseline exercise stress test. Participants received a health watch, which monitored heart rate and physical activity, and a tablet computer with an app that displayed progress toward accomplishing weekly walking and exercise goals. Results were transmitted to a cardiac rehabilitation nurse via a secure connection. For 12 weeks, participants exercised at home and also participated in weekly phone counseling sessions with the nurse, who provided personalized cardiac rehabilitation solutions and standard cardiac rehabilitation education. We assessed usability of the system, adherence to weekly exercise and walking goals, counseling session attendance, and disease-specific quality of life. RESULTS Of 18 participants (age: mean 59 years, SD 7) who completed the 12-week telerehabilitation program, 6 (33%) were women, and 6 (33%) had ST-elevation myocardial infarction. Participants wore the health watch for a median of 12.7 hours (IQR 11.1, 13.8) per day and completed a median of 86% of exercise goals. Participants, on average, walked 121 minutes per week (SD 175) and spent 189 minutes per week (SD 210) in their target exercise heart rate zone. Overall, participants found the system to be highly usable (System Usability Scale score: median 83, IQR 65, 100). CONCLUSIONS This pilot study established the feasibility of delivering cardiac telerehabilitation at home to acute myocardial infarction survivors via a health watch-based program and telephone counseling sessions. Usability and adherence to health watch use, exercise recommendations, and counseling sessions were high. Further studies are warranted to compare patient outcomes and health care resource utilization between center-based rehabilitation and telerehabilitation.
Collapse
Affiliation(s)
- Eric Y Ding
- Division of Cardiology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, United States
| | - Nathaniel Erskine
- Department of Anesthesiology, Duke University, Durham, NC, United States
| | - Wim Stut
- Philips Research, Eindhoven, Netherlands
| | - David D McManus
- Division of Cardiology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, United States
| | - Amy Peterson
- University of Massachusetts Memorial Marlborough Hospital, Marlborough, MA, United States
| | - Ziyue Wang
- Division of Cardiology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, United States
| | | | - Daniella Albuquerque
- Division of Cardiology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, United States
| | - Alvaro Alonso
- Division of Cardiology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, United States
| | - Naomi F Botkin
- Division of Cardiology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, United States
| | - Quinn R Pack
- Division of Cardiology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, United States
| | - David D McManus
- Division of Cardiology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, United States
| |
Collapse
|
15
|
Singh N, Peterson A, Baraff A, Korpak A, Vaughan-Sarrazin M, Smith N, Curtis J, Weiss N. POS0287 USE OF BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN RELATION TO THE RISK OF LYMPHOMA: A COHORT STUDY OF US VETERANS WITH RHEUMATOID ARTHRITIS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Epidemiologic studies suggest that disease duration and degree of inflammatory activity of rheumatoid arthritis (RA) contribute to lymphoma development. However, the association of the use of biologic disease modifying anti-rheumatic drugs (bDMARDs) in patients with RA on lymphoma risk needs further evaluation.Objectives:Examine the effect of administration of bDMARDS on the incidence of lymphoma in an inception cohort of RA.Methods:We identified patients diagnosed with RA in any US Veterans Affairs (VA) facility from 1/1/2002 and 12/31/2018 using the Veteran’s Health Administration (VHA) databases. To be included, each patient was required to meet the following criteria: 1) 2+ RA diagnostic codes at least 7 days apart but no more than 365 days apart 2) a prescription for a conventional synthetic DMARD (csDMARD) within 90 days of the first RA diagnosis 3) One inpatient or outpatient visit 30 days to 2 years preceding first RA diagnosis (indicating they are a regular user of the VHA). We excluded patients for any of the following if they preceded the first RA diagnosis: 1) a prior single RA diagnostic code 2) a prescription for any DMARD medication 3) a concomitant diagnosis of another inflammatory arthritis (e.g. psoriatic arthropathy) 4) a diagnosis of lymphoma. Index date for the study is the date of the first qualifying RA diagnosis. Lymphoma diagnoses were identified through VHA records using the International Classification of Diseases-Oncology codes.Results:We identified 27,536 veterans with RA in the study period meeting the inclusion and exclusion criteria. Of these, 53% (n=14,705) were in the age range 60 to 80 years. The cohort was 89% male, 75.5% White, 13.7% African American. Over the study period, 1.2% (n=332) of the study population developed a lymphoma.Conclusion:Using the nationwide VHA we have identified a large inception cohort of patients with RA of whom 1.2% developed lymphoma over study follow-up. This data will be used in future analyses to produce estimates of the effect of biologic medications on lymphoma risk, adjusting for confounding by indication and other variables.Table 1.Baseline characteristics of the cohort based on bDMARD exposure statusCharacteristicbDMARD-naive (n= 19,095)bDMARD-exposed (n=8,441)Overall Lymphomas Age (years)171161 18-4046 40-606378 60-8010074 >8043 Males17,206 (90%)7,270 (86%)Race White14,150 (74%)6,627 (76%) Black2,674 (14%)1,090 (13%) Asian96 (0.5%)46 (0.5%) Native American or Pacific Islander371 (2%)187 (2.2%) Missing1,804 (9%)491 (6%)Acknowledgements:The work in this abstract is supported by Investigator Award from the Rheumatology Research Foundation to Dr Singh.Disclosure of Interests:None declared
Collapse
|
16
|
Matsubayashi H, Mountain J, Peterson A, Inoue T. Disordered Region in PI3K Regulatory Subunit p85 Drives Clathrin‐dependent Endocytosis and Regulates Cell Motility. FASEB J 2021. [DOI: 10.1096/fasebj.2021.35.s1.01941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
17
|
Enright C, Peterson A, Eickhoff J, Dodge A. Statin adherence and LDL-C reduction in a pediatric population. Progress in Pediatric Cardiology 2020. [DOI: 10.1016/j.ppedcard.2020.101210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
18
|
Sirdenis TK, Harper GW, Carrillo MD, Jadwin-Cakmak L, Loveluck J, Pingel ES, Benton A, Peterson A, Pollard R, Bauermeister JA. Toward Sexual Health Equity for Gay, Bisexual, and Transgender Youth: An Intergenerational, Collaborative, Multisector Partnerships Approach to Structural Change. Health Educ Behav 2020; 46:88S-99S. [PMID: 31549560 DOI: 10.1177/1090198119853607] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background. Gay, bisexual, and transgender youth (GBTY) experience sexual health inequities and contend with intersectional oppression. The Michigan Forward in Enhancing Research and Community Equity (MFierce) Coalition formed as an intergenerational, collaborative, multisector partnership with a focus on implementing community-identified policy, systems, and environmental (PSE) change strategies to address inequities and injustices. Aims. We describe MFierce coalition development and structural change activities organized within Collaborating for Equity and Justice (CEJ) principles and provide empirical data supporting the utility of such principles. Method. We prioritized leadership by GBTY and created personal and professional capacity-building activities to support GBTY in being change agents. Our work was grounded in community-engaged scholarship and used a shared-power community development process. Our PSE change intervention, the Health Access Initiative (HAI), was a structural change program for health facilities aimed at improving the quality of and access to sexual health care for GBTY. Results. We evaluated coalition functioning and activities through multimethod assessments and evaluated PSE changes through HAI participant surveys. Data demonstrated positive and steady coalition dynamics, multiple benefits of participation for GBTY, and strategies for collaborative multigenerational community work. HAI outcome data revealed significant increases in PSE changes. Discussion. Centering life experiences of GBTY in collaborative partnerships and building opportunities for professional and personal development can support sustainable community change. We offer recommendations for developing future intergenerational, collaborative, multisector partnerships that prioritize youth leadership. Conclusion. Collaborative methods and careful consideration of adult-youth dynamics can inform future transformative efforts focused on health equity and justice for GBTY.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Amy Peterson
- Michigan Department of Health and Human Services, Lansing, MI, USA
| | | | | |
Collapse
|
19
|
Ruan L, McNamara JT, Zhang X, Chang ACC, Zhu J, Dong Y, Sun G, Peterson A, Na CH, Li R. Solid-phase inclusion as a mechanism for regulating unfolded proteins in the mitochondrial matrix. Sci Adv 2020; 6:eabc7288. [PMID: 32821848 PMCID: PMC7406381 DOI: 10.1126/sciadv.abc7288] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/10/2020] [Accepted: 06/22/2020] [Indexed: 05/05/2023]
Abstract
Proteostasis declines with age, characterized by the accumulation of unfolded or damaged proteins. Recent studies suggest that proteins constituting pathological inclusions in neurodegenerative diseases also enter and accumulate in mitochondria. How unfolded proteins are managed within mitochondria remains unclear. Here, we found that excessive unfolded proteins in the mitochondrial matrix of yeast cells are consolidated into solid-phase inclusions, which we term deposits of unfolded mitochondrial proteins (DUMP). Formation of DUMP occurs in mitochondria near endoplasmic reticulum-mitochondria contact sites and is regulated by mitochondrial proteins controlling the production of cytidine 5'-diphosphate-diacylglycerol. DUMP formation is age dependent but accelerated by exogenous unfolded proteins. Many enzymes of the tricarboxylic acid cycle were enriched in DUMP. During yeast cell division, DUMP formation is necessary for asymmetric inheritance of damaged mitochondrial proteins between mother and daughter cells. We provide evidence that DUMP-like structures may be induced by excessive unfolded proteins in human cells.
Collapse
Affiliation(s)
- Linhao Ruan
- Center for Cell Dynamics and Department of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
- Biochemistry, Cellular and Molecular Biology (BCMB) Graduate Program, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
| | - Joshua T. McNamara
- Center for Cell Dynamics and Department of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
- Biochemistry, Cellular and Molecular Biology (BCMB) Graduate Program, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
| | - Xi Zhang
- Center for Cell Dynamics and Department of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Alexander Chih-Chieh Chang
- Center for Cell Dynamics and Department of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
- Department of Chemical and Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD 21218, USA
| | - Jin Zhu
- Center for Cell Dynamics and Department of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Yi Dong
- Center for Cell Dynamics and Department of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
- Immunology Graduate Program, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
| | - Gordon Sun
- Center for Cell Dynamics and Department of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
- Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21218, USA
| | - Amy Peterson
- Biochemistry, Cellular and Molecular Biology (BCMB) Graduate Program, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
| | - Chan Hyun Na
- Department of Neurology, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Rong Li
- Center for Cell Dynamics and Department of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
- Department of Chemical and Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD 21218, USA
- Mechanobiology Institute and Department of Biological Science, National University of Singapore, Singapore 117411, Singapore
| |
Collapse
|
20
|
Wu CCC, Peterson A, Zinshteyn B, Regot S, Green R. Ribosome Collisions Trigger General Stress Responses to Regulate Cell Fate. Cell 2020; 182:404-416.e14. [PMID: 32610081 PMCID: PMC7384957 DOI: 10.1016/j.cell.2020.06.006] [Citation(s) in RCA: 198] [Impact Index Per Article: 49.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2020] [Revised: 05/18/2020] [Accepted: 06/02/2020] [Indexed: 01/01/2023]
Abstract
Problems arising during translation of mRNAs lead to ribosome stalling and collisions that trigger a series of quality control events. However, the global cellular response to ribosome collisions has not been explored. Here, we uncover a function for ribosome collisions in signal transduction. Using translation elongation inhibitors and general cellular stress conditions, including amino acid starvation and UV irradiation, we show that ribosome collisions activate the stress-activated protein kinase (SAPK) and GCN2-mediated stress response pathways. We show that the MAPKKK ZAK functions as the sentinel for ribosome collisions and is required for immediate early activation of both SAPK (p38/JNK) and GCN2 signaling pathways. Selective ribosome profiling and biochemistry demonstrate that although ZAK generally associates with elongating ribosomes on polysomal mRNAs, it specifically auto-phosphorylates on the minimal unit of colliding ribosomes, the disome. Together, these results provide molecular insights into how perturbation of translational homeostasis regulates cell fate.
Collapse
Affiliation(s)
- Colin Chih-Chien Wu
- Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Amy Peterson
- Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Boris Zinshteyn
- Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Sergi Regot
- Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Rachel Green
- Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
| |
Collapse
|
21
|
Block R, Bang M, Wong N, Peterson A, Karalis D. Primary Care Physician and Cardiologist Characteristics Predicting Diagnosis and Treatment of Patients with Familial Hypercholesterolemia. J Clin Lipidol 2020. [DOI: 10.1016/j.jacl.2020.05.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
22
|
Karalis D, Bang M, Block R, Peterson A, Wong N. Both Cardiologists and Primary Care Physicians Lack Awareness in How to Recognize and Treat Heterozygous Familial Hypercholesterolemia†. J Clin Lipidol 2020. [DOI: 10.1016/j.jacl.2020.05.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
23
|
Peterson A, Bang M, Block R, Wong N, Karalis D. Primary Care Physician and Cardiologist Cascade Screening Behaviors and Treatment Recommendations for Patients with Familial Hypercholesterolemia. J Clin Lipidol 2020. [DOI: 10.1016/j.jacl.2020.05.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
24
|
Zhang D, Guelfi S, Garcia-Ruiz S, Costa B, Reynolds RH, D'Sa K, Liu W, Courtin T, Peterson A, Jaffe AE, Hardy J, Botía JA, Collado-Torres L, Ryten M. Incomplete annotation has a disproportionate impact on our understanding of Mendelian and complex neurogenetic disorders. Sci Adv 2020; 6:6/24/eaay8299. [PMID: 32917675 PMCID: PMC7286675 DOI: 10.1126/sciadv.aay8299] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Accepted: 04/07/2020] [Indexed: 05/02/2023]
Abstract
Growing evidence suggests that human gene annotation remains incomplete; however, it is unclear how this affects different tissues and our understanding of different disorders. Here, we detect previously unannotated transcription from Genotype-Tissue Expression RNA sequencing data across 41 human tissues. We connect this unannotated transcription to known genes, confirming that human gene annotation remains incomplete, even among well-studied genes including 63% of the Online Mendelian Inheritance in Man-morbid catalog and 317 neurodegeneration-associated genes. We find the greatest abundance of unannotated transcription in brain and genes highly expressed in brain are more likely to be reannotated. We explore examples of reannotated disease genes, such as SNCA, for which we experimentally validate a previously unidentified, brain-specific, potentially protein-coding exon. We release all tissue-specific transcriptomes through vizER: http://rytenlab.com/browser/app/vizER We anticipate that this resource will facilitate more accurate genetic analysis, with the greatest impact on our understanding of Mendelian and complex neurogenetic disorders.
Collapse
Affiliation(s)
- David Zhang
- Institute of Neurology, University College London (UCL), London, UK
- NIHR Great Ormond Street Hospital Biomedical Research Centre, University College London, London, UK
- Genetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University College London, London WC1E 6BT, UK
| | - Sebastian Guelfi
- Institute of Neurology, University College London (UCL), London, UK
| | - Sonia Garcia-Ruiz
- Institute of Neurology, University College London (UCL), London, UK
- NIHR Great Ormond Street Hospital Biomedical Research Centre, University College London, London, UK
- Genetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University College London, London WC1E 6BT, UK
| | - Beatrice Costa
- Institute of Neurology, University College London (UCL), London, UK
| | | | - Karishma D'Sa
- Institute of Neurology, University College London (UCL), London, UK
| | - Wenfei Liu
- Institute of Neurology, University College London (UCL), London, UK
| | - Thomas Courtin
- Sorbonne Universités, UPMC Université Paris 06, UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM, Paris, France
| | - Amy Peterson
- Lieber Institute for Brain Development, Baltimore, MD, USA
| | - Andrew E Jaffe
- Lieber Institute for Brain Development, Baltimore, MD, USA
- Center for Computational Biology, Johns Hopkins University, Baltimore, MD, USA
- Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA
- McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
| | - John Hardy
- Institute of Neurology, University College London (UCL), London, UK
- UK Dementia Research Institute at UCL and Department of Neurodegenerative Disease, UCL Institute of Neurology, University College London, London, UK
- Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, 1 Wakefield Street, London WC1N 1PJ, UK
- NIHR, University College London Hospitals, Biomedical Research Centre, London, UK
- Institute for Advanced Study, The Hong Kong University of Science and Technology, Hong Kong SAR, China
| | - Juan A Botía
- Institute of Neurology, University College London (UCL), London, UK
- Departamento de Ingeniería de la Información y las Comunicaciones, Universidad de Murcia, 30100 Murcia, Spain
| | - Leonardo Collado-Torres
- Lieber Institute for Brain Development, Baltimore, MD, USA
- Center for Computational Biology, Johns Hopkins University, Baltimore, MD, USA
| | - Mina Ryten
- Institute of Neurology, University College London (UCL), London, UK.
- NIHR Great Ormond Street Hospital Biomedical Research Centre, University College London, London, UK
- Genetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University College London, London WC1E 6BT, UK
| |
Collapse
|
25
|
Villarreal B, Foster S, Hansen S, Brock M, Sanchez H, Gerwell K, Carrizales F, Peterson A, Pruiksma K, Mysliwiec V. 0860 Sleep Disorders In Female Military Personnel. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Sleep is an essential biological function and the disruption of sleep has deleterious consequences. Military personnel experience unique stressors related to their service, elevating the risk of developing sleep disorders. The etiologies and impact of sleep disorders on military women’s health is poorly understood. This study is the first to prospectively assess whether military women with insomnia, obstructive sleep apnea (OSA), or comorbid insomnia and OSA (COMISA) have different gender roles, military service-associated factors, and biological characteristics than military men with the same disorders.
Methods
This is a prospective observational study of military personnel with sleep disturbances. The study will evaluate women and men matched for sleep disorder. Participants will complete an evaluation to include polysomnography (PSG), sleep questionnaires and validated clinical assessments of associated disorders of interest. The baseline demographics, questionnaire, and PSG results will be analyzed to assess for commonalities or differences between genders.
Results
We have enrolled 45 patients (24% female). Males had a higher BMI (29.1) than females (26). Males were also older (38) than females (35). The leading diagnosis in males was OSA (44%) and insomnia in females (64%). In males, the apnea-hypopnea index (AHI) was 11.3/hr, arousal index (ARI) was 20/hr, and sleep efficiency (SE) was 86.5%. Total sleep time (TST), wake after sleep onset (WASO), and sleep onset latency (SOL) were 364.6, 40.9, and 12.6 minutes, respectively. In females, the average AHI was 6.6/hr, ARI was 15/hr, and SE was 87.2%. Their TST, WASO, and SOL were 359, 44, and 12.6 minutes, respectively.
Conclusion
Military personnel are at increased risk of sleep disorders. Literature comparing male and female characteristics and sleep disorders is scarce. In this study, baseline demographics were similar in both groups but insomnia was the leading diagnosis for women. This emphasizes the importance of adequate recognition and treatment of insomnia in this group.
Support
This study is supported by the Defense Health Agency, Defense Medical Research and Development Program, Clinical Research Intramural Initiative for Military Women’s Health.
Collapse
Affiliation(s)
- B Villarreal
- San Antonio Military Healthcare System, Lackland AFB, TX
| | - S Foster
- San Antonio Military Healthcare System, Lackland AFB, TX
| | - S Hansen
- San Antonio Military Healthcare System, Lackland AFB, TX
| | - M Brock
- San Antonio Military Healthcare System, Lackland AFB, TX
| | - H Sanchez
- San Antonio Military Healthcare System, Lackland AFB, TX
| | - K Gerwell
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - F Carrizales
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - A Peterson
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - K Pruiksma
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - V Mysliwiec
- San Antonio Military Healthcare System, Lackland AFB, TX
| |
Collapse
|
26
|
Taylor D, Bunnell B, Calhoun C, Pruiksma K, Dietch J, Wardle-Pinkston S, Milanak M, Rheingold A, Simmons R, Peterson A, Morin C, Ruggiero K, Brim W, Dolan D, Wilkerson A. 1186 Developing And Testing A Web-based Provider Training For Cognitive Behavioral Therapy Of Insomnia. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.1180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Chronic insomnia is a common, debilitating disorder and a risk factor for significant medical morbidity, mental health problems, and workplace difficulties. Cognitive behavioral therapy for insomnia (CBT-I) is the gold standard treatment for insomnia. However, few providers are trained in CBT-I, in part due to a bottleneck in training availability and the time and cost associated with current training platforms. To address this training deficit, our team developed and evaluated CBTIweb.org, a web-based provider training course for CBT-I.
Methods
Feedback from alpha- and beta-testing of CBTIweb.org was collected and used to optimize course content and functionality. Then, a comparison study was conducted in which licensed providers were randomized to complete either the online CBTIweb.org course (n=21) or an in-person CBT-I training (n=23). During all phases of development, providers completed a Computer System Usability Questionnaire (CSUQ), investigator-developed website usability and content questionnaires, and pre/post-training competency assessments.
Results
Independent samples t-tests indicated significant improvements in CSUQ, and website usability and content questionnaires responses from alpha- to beta-testing (all ps < .05). Linear mixed-effects modeling revealed significant within-subject increases in knowledge acquisition (F(34.7) = 65.4, p < 0.001; baseline = 69% correct, post-training = 92% correct) when collapsed across in-person and web-based groups. The interaction group by time interaction was non-significant (F(34.7) = 1.7, p = 0.204), indicating similar gains in knowledge (i.e., equivalence) between the in-person and the CBTIweb.org training formats.
Conclusion
Alpha and beta testers of CBTIweb.org reported high levels of satisfaction while also noting areas for improvement, which were used to update the site. Findings suggest the final CBTIweb.org product successfully trained clinicians compared to an in-person workshop, given knowledge acquisition improvements. CBTIweb.org is an efficient and effective training platform for clinicians to gain knowledge and competence in the most effective treatment for insomnia.
Support
W81XWH-17-1-0165
Collapse
Affiliation(s)
- D Taylor
- University of Arizona, Tucson, AZ
| | - B Bunnell
- Medical University of South Carolina, Charleston, SC
| | - C Calhoun
- Medical University of South Carolina, Charleston, SC
| | | | - J Dietch
- University of North Texas, Denton, TX
| | | | - M Milanak
- Medical University of South Carolina, Charleston, SC
| | - A Rheingold
- Medical University of South Carolina, Charleston, SC
| | - R Simmons
- Medical University of South Carolina, Charleston, SC
| | | | - C Morin
- Laval University, Quebec, QC, CANADA
| | - K Ruggiero
- Medical University of South Carolina, Charleston, SC
| | - W Brim
- Center for Deployment Psychology, Bethesda, MD
| | - D Dolan
- Center for Deployment Psychology, Bethesda, MD
| | - A Wilkerson
- Medical University of South Carolina, Charleston, SC
| |
Collapse
|
27
|
Pruiksma KE, Hale W, Mintz J, Peterson A, Young-McCaughan S, Wilkerson A, Nicholson K, Dondanville K, Fina B, Borah E, Roache J, Litz BT, Bryan C, Taylor DJ. 0483 Predictors of Cognitive Behavioral Therapy for Insomnia (CBT) Outcomes in Active Duty U.S. Army Personnel. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.480] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Cognitive behavioral therapy for insomnia (CBTi) is well established as the first-line treatment for the management of chronic insomnia. Identifying predictors of response to CBTi should enable the field to efficiently utilize resources to treat those who are likely to respond and to personalize treatment approaches to optimize outcomes for those who are less likely to respond to traditional CBTi. Although a range of studies have been conducted, no clear pattern of predictors of response to CBTi has emerged.
Methods
The purpose of this study was to examine the impact and relative importance of a comprehensive group of pretreatment predictors of insomnia outcomes in 99 active duty service members who received in-person CBTi in a randomized clinical trial.
Results
Results indicated that higher levels of baseline insomnia severity and total sleep time predicted greater improvements on the Insomnia Severity Index (ISI) following treatment. Higher depression symptoms and a history of head injury predicted a worse response to treatment (i.e., smaller improvements on the ISI).
Conclusion
Clinically meaningful improvements, as measured by the reliable change index (RCI), were found in 59% of the sample. Over and above baseline insomnia severity, only depressive symptoms predicted this outcome. Future studies should examine if modifications to CBTi based on these predictors of response can improve outcomes.
Support
This study was conducted with support from the U.S. Department of Defense through the U.S. Army Medical Research and Materiel Command, Congressionally Directed Medical Research Programs, Psychological Health and Traumatic Brain Injury Research Program award W81XWH-10-1-0828 (PI: Dr Taylor).
Collapse
Affiliation(s)
- K E Pruiksma
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - W Hale
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - J Mintz
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - A Peterson
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - S Young-McCaughan
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - A Wilkerson
- Medical University of South Carolina, Charleston, SC
| | - K Nicholson
- Carl R Darnall Army Medical Center, Fort Hood, TX
| | - K Dondanville
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - B Fina
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - E Borah
- University of Texas at Austin, Austin, TX
| | - J Roache
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - B T Litz
- Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA
| | - C Bryan
- University of Utah, Salt Lake City, UT
| | | |
Collapse
|
28
|
Miles SR, Pruiksma K, Slavish D, Nakase-Richardson R, Nicholson K, Wardle S, Young-McCaughan S, Resick P, Williamson D, Dondanville K, Litz B, Mintz J, Keane T, Peterson A, Taylor D. 1073 Sleep Disorders Contribute To Anger In Service Members With Posttraumatic Stress Disorder. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.1069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
The emotion of anger and behavioral acts of aggression can lead to severe negative consequences, including family violence, legal charges, and death. Anger can be a symptom of posttraumatic stress disorder (PTSD), particularly in service members. Service members report difficulties managing their anger and trouble with the subsequent results. Factors that differentiate service members with PTSD who have anger related problems from those who do not are still unknown. Impaired sleep is associated with negative mood states in the general population and may be a risk factor for anger in those with PTSD. This project examines how sleep disorders commonly diagnosed in service members (i.e., obstructive sleep apnea and insomnia) relate to PTSD and anger.
Methods
Ninety-three service members with comorbid PTSD, insomnia, and nightmares (mean age = 35.86 years, SD = 8.38, 27% female, 45% white) completed polysomnography and other measures as part of a clinical trial. A multiple regression model examined how total Apnea Hypopnea Index (AHI), AHI during REM sleep, insomnia (Insomnia Severity Index), age, and race related to PTSD symptoms (Clinical Administered PTSD Scale-5: CAPS-5). A second multiple regression model examined the same variables’ associations with anger (Dimensions of Anger Reactions-5; DAR-5).
Results
More than a third of the sample (37%) met criteria for OSA (AHI scores>5) and 99% met criteria for insomnia (ISI>10). Total AHI and REM AHI were not associated with CAPS-5 scores or ISI. Across OSA and PSG indices, only greater REM AHI (b=.07, p<.05) and Insomnia (b=.43, p<.05) were positively associated with DAR-5 anger scores. Total AHI was unrelated to anger.
Conclusion
Elevated REM AHI and insomnia were associated with greater anger in service members with PTSD. Current treatments for anger are only moderately effective. Assessing and treating comorbid sleep disorders may reduce anger and enhance successful PTSD treatment.
Support
Consortium to Alleviate PTSD (W81XWH-13-2-0065), DVA (I01CX001136-01), GDHS (W91YTZ-13-C-0015) for DVBIC.
Collapse
Affiliation(s)
- S R Miles
- James A. Haley Veterans’ Hospital, Tampa, FL
| | - K Pruiksma
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - D Slavish
- University of North Texas, 76203, TX
| | | | - K Nicholson
- Carl D. Darnall Army Medical Center, Fort Hood, TX
| | - S Wardle
- The University of Arizona, Tucson, AZ
| | - S Young-McCaughan
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | | | | | - K Dondanville
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - B Litz
- VA Boston Healthcare System, Boston, MA
| | - J Mintz
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - T Keane
- VA Boston Healthcare System, Boston, MA
| | - A Peterson
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - D Taylor
- The University of Arizona, Tucson, AZ
| |
Collapse
|
29
|
Karalis D, Wong ND, Block R, Peterson A. HOW WELL DO CARDIOLOGISTS AND PRIMARY CARE PHYSICIANS RECOGNIZE AND TREAT HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: A SURVEY FROM THE NATIONAL LIPID ASSOCIATION. J Am Coll Cardiol 2020. [DOI: 10.1016/s0735-1097(20)32589-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
30
|
Foley J, Tinoco-Gracia L, Rodriguez-Lomelí M, Estrada-Guzmán J, Fierro M, Mattar-Lopez E, Peterson A, Pascoe E, Gonzalez Y, Hori-Oshima S, Armstrong PA, Lopez G, Jacome-Ibarra M, Paddock CD, Zazueta OE. Unbiased Assessment of Abundance of Rhipicephalus sanguineus sensu lato Ticks, Canine Exposure to Spotted Fever Group Rickettsia, and Risk Factors in Mexicali, México. Am J Trop Med Hyg 2020; 101:22-32. [PMID: 31094313 DOI: 10.4269/ajtmh.18-0878] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
An epidemic of Rocky Mountain spotted fever (RMSF) is ongoing in Mexicali, México. We visited 100 neighborhoods with diagnosed human cases and 100 control neighborhoods to evaluate knowledge of the epidemic; obtain data on the spatial distribution of dogs, canine seroprevalence and active infection, tick infestations, and presence of rickettsial DNA in ticks; and evaluate risk factors for human cases, seropositivity, and tick infestation within an unbiased study design. The majority (80%) of residents had heard of RMSF, but only 48% used acaricides in the home or on dogs. Case neighborhoods and those with high canine seroprevalence tended to be on the city periphery or in the agricultural valley. No dogs were polymerase chain reaction (PCR) positive for Rickettsia rickettsii, and the overall seroprevalence was 65% (titers from 64 to 1,024). PCR prevalence in ticks was 0.70%, confirmed by DNA sequencing as R. rickettsii; neighborhood prevalence ranged from 0.7% to 6.1%. Twelve percent of dogs had high tick burdens, and all ticks were Rhipicephalus sanguineus. Epidemiologically significant risk factors were ground covering for a neighborhood having a human case; dogs having poor body condition and weighing < 10 kg for canine seropositivity; dogs living at the home for the number of ticks in the environment; and being near canals, having trash on the patio, and a dog being thin for tick burdens on dogs. A One Health approach is crucial to understanding RMSF and brown dog ticks.
Collapse
Affiliation(s)
- Janet Foley
- Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, California
| | - Luis Tinoco-Gracia
- Laboratorio de Salud Pública Veterinaria, Instituto de Investigaciones en Ciencias Veterinarias, Universidad Autónoma de Baja California, Mexicali, México
| | | | | | - Maria Fierro
- Public Health Department, Imperial County, California
| | - Elva Mattar-Lopez
- Facultad de Medicina, Universidad Autónoma de Baja California, Mexicali, México
| | - Amy Peterson
- Rickettsial Zoonoses Branch, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Emily Pascoe
- Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, California
| | - Yolanda Gonzalez
- Laboratorio de Salud Pública Veterinaria, Instituto de Investigaciones en Ciencias Veterinarias, Universidad Autónoma de Baja California, Mexicali, México
| | - Sawako Hori-Oshima
- Laboratorio de Salud Pública Veterinaria, Instituto de Investigaciones en Ciencias Veterinarias, Universidad Autónoma de Baja California, Mexicali, México
| | - Paige A Armstrong
- Rickettsial Zoonoses Branch, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Gilberto Lopez
- Laboratorio de Salud Pública Veterinaria, Instituto de Investigaciones en Ciencias Veterinarias, Universidad Autónoma de Baja California, Mexicali, México
| | - Mariana Jacome-Ibarra
- Laboratorio de Salud Pública Veterinaria, Instituto de Investigaciones en Ciencias Veterinarias, Universidad Autónoma de Baja California, Mexicali, México
| | - Christopher D Paddock
- Rickettsial Zoonoses Branch, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Oscar E Zazueta
- Dirección de Enseñanza y Vinculación, Instituto de Servicios de Salud Pública del Estado de Baja California, Mexicali, México
| |
Collapse
|
31
|
Collado-Torres L, Burke EE, Peterson A, Shin J, Straub RE, Rajpurohit A, Semick SA, Ulrich WS, Price AJ, Valencia C, Tao R, Deep-Soboslay A, Hyde TM, Kleinman JE, Weinberger DR, Jaffe AE. Regional Heterogeneity in Gene Expression, Regulation, and Coherence in the Frontal Cortex and Hippocampus across Development and Schizophrenia. Neuron 2019; 103:203-216.e8. [PMID: 31174959 DOI: 10.1016/j.neuron.2019.05.013] [Citation(s) in RCA: 118] [Impact Index Per Article: 23.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2018] [Revised: 04/08/2019] [Accepted: 05/06/2019] [Indexed: 02/06/2023]
Abstract
The hippocampus formation, although prominently implicated in schizophrenia pathogenesis, has been overlooked in large-scale genomics efforts in the schizophrenic brain. We performed RNA-seq in hippocampi and dorsolateral prefrontal cortices (DLPFCs) from 551 individuals (286 with schizophrenia). We identified substantial regional differences in gene expression and found widespread developmental differences that were independent of cellular composition. We identified 48 and 245 differentially expressed genes (DEGs) associated with schizophrenia within the hippocampus and DLPFC, with little overlap between the brain regions. 124 of 163 (76.6%) of schizophrenia GWAS risk loci contained eQTLs in any region. Transcriptome-wide association studies in each region identified many novel schizophrenia risk features that were brain region-specific. Last, we identified potential molecular correlates of in vivo evidence of altered prefrontal-hippocampal functional coherence in schizophrenia. These results underscore the complexity and regional heterogeneity of the transcriptional correlates of schizophrenia and offer new insights into potentially causative biology.
Collapse
Affiliation(s)
- Leonardo Collado-Torres
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD 21205, USA; Center for Computational Biology, Johns Hopkins University, Baltimore, MD 21205, USA
| | - Emily E Burke
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD 21205, USA
| | - Amy Peterson
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD 21205, USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
| | - JooHeon Shin
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD 21205, USA
| | - Richard E Straub
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD 21205, USA
| | - Anandita Rajpurohit
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD 21205, USA
| | - Stephen A Semick
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD 21205, USA
| | - William S Ulrich
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD 21205, USA
| | | | - Amanda J Price
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD 21205, USA; McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Cristian Valencia
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD 21205, USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
| | - Ran Tao
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD 21205, USA
| | - Amy Deep-Soboslay
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD 21205, USA
| | - Thomas M Hyde
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD 21205, USA; Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
| | - Joel E Kleinman
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD 21205, USA; Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
| | - Daniel R Weinberger
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD 21205, USA; McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA; Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
| | - Andrew E Jaffe
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD 21205, USA; Center for Computational Biology, Johns Hopkins University, Baltimore, MD 21205, USA; McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
| |
Collapse
|
32
|
Quilter L, Cyr SS, Abitria V, Ancharski A, Bautista I, Bazan J, Carifo K, Ervin M, Harrison R, Hoogenboom A, Peterson A, Pham C, Snyder B, Turner AN, Torrone E. 125. eGISP: Enhanced Surveillance of Neisseria gonorrhoeae Antimicrobial Susceptibility in the United States. Open Forum Infect Dis 2018. [PMCID: PMC6253014 DOI: 10.1093/ofid/ofy209.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
Abstract
Background The Gonococcal Isolate Surveillance Project (GISP), which monitors trends in N. gonorrhoeae susceptibility among men with gonococcal urethritis in sexually transmitted disease (STD) clinics, has informed treatment recommendations for 3 decades. However, it has been speculated that susceptibility patterns may differ in women, as well as in the pharynx and rectum. We describe preliminary findings from the enhanced GISP (eGISP), which expands surveillance to pharyngeal, rectal, and endocervical isolates. Methods In August 2017, select jurisdictions were funded to collect urogenital and extragenital specimens from men and women seen in participating STD clinics. Positive gonorrhea cultures were sent to regional laboratories for antimicrobial susceptibility testing (AST) by agar dilution. Isolates with elevated minimum inhibitory concentration (MIC) to azithromycin (AZI) (MIC ≥2.0 μg/mL), cefixime (CFX) (MIC ≥0.25 μg/mL), and/or ceftriaxone (CRO) (MIC ≥0.125 μg/mL) were designated as Alert isolates. Clinical and epidemiological data were linked to AST results. Results From August 2017 to February 2018, 4 clinics in 4 jurisdictions submitted 468 positive gonococcal specimens for AST; 36.1% were from men who have sex with men (MSM), 51.9% from men who have sex with women (MSW), and 12.0% from women. Overall, 71.8% were urethral, 7.9% endocervical, 7.1% rectal, and 13.2% pharyngeal. Seventy-two isolates (15.4%) were Alerts: 97.2% (N = 70) had elevated MICs to AZI, 2.8% (N = 2) had elevated MICs to CFX, and none had elevated MICs to CRO. No isolate had elevated MICs to both AZI and CFX. Among MSM, 15.9% of urogenital isolates and 16.1% of extragenital isolates had an elevated AZI MIC. Among MSW, 11.8% of urogenital isolates and 14.3% of pharyngeal isolates had an elevated AZI MIC. Among women, 24.3% of endocervical isolates and 26.3% of extragenital isolates had an elevated AZI MIC. Conclusion Preliminary eGISP data suggest that enhanced surveillance of pharyngeal, rectal, and endocervical isolates is feasible and that elevated MICs to azithromycin are common among males and females. Including isolates from extragenital anatomic sites and women may help strengthen N. gonorrhoeae surveillance capacity. Disclosures All authors: No reported disclosures.
Collapse
Affiliation(s)
- Laura Quilter
- Centers for Disease Control and Prevention, Division of STD Prevention, Atlanta, Georgia
| | - Sancta St Cyr
- Centers for Disease Control and Prevention, Division of STD Prevention, Atlanta, Georgia
| | | | - Andrew Ancharski
- Philadelphia Department of Public Health, Philadelphia, Pennsylvania
| | - Ilene Bautista
- Southern Nevada Public Health Laboratory, Las Vegas, Nevada
| | - Jose Bazan
- The Ohio State University College of Medicine, Columbus, Ohio
| | - Karen Carifo
- Southern Nevada Public Health Laboratory, Las Vegas, Nevada
| | | | - Rebecca Harrison
- Kalamazoo County Health and Community Services, Kalamazoo, Michigan
| | - Aaron Hoogenboom
- Kalamazoo County Health and Community Services, Kalamazoo, Michigan
| | - Amy Peterson
- Michigan Department of Community Health, Lansing, Michigan
| | - Cau Pham
- Centers for Disease Control and Prevention, Division of STD Prevention, Atlanta, Georgia
| | - Brandon Snyder
- The Ohio State University College of Medicine, Columbus, Ohio
| | | | - Elizabeth Torrone
- Centers for Disease Control and Prevention, Division of STD Prevention, Atlanta, Georgia
| |
Collapse
|
33
|
Straily A, Dahlgren FS, Peterson A, Paddock CD. Surveillance for Q Fever Endocarditis in the United States, 1999-2015. Clin Infect Dis 2018; 65:1872-1877. [PMID: 29140515 DOI: 10.1093/cid/cix702] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2017] [Accepted: 08/04/2017] [Indexed: 01/01/2023] Open
Abstract
Background Q fever is a worldwide zoonosis caused by Coxiella burnetii. In some persons, particularly those with cardiac valve disease, infection with C. burnetii can cause a life-threatening infective endocarditis. There are few descriptive analyses of Q fever endocarditis in the United States. Methods Q fever case report forms submitted during 1999-2015 were reviewed to identify reports describing endocarditis. Cases were categorized as confirmed or probable using criteria defined by the Council for State and Territorial Epidemiologists (CSTE). Demographic, laboratory, and clinical data were analyzed. Results Of 140 case report forms reporting endocarditis, 49 met the confirmed definition and 36 met the probable definition. Eighty-two percent were male and the median age was 57 years (range, 16-87 years). Sixty-seven patients (78.8%) were hospitalized, and 5 deaths (5.9%) were reported. Forty-five patients (52.9%) had a preexisting valvulopathy. Eight patients with endocarditis had phase I immunoglobulin G antibody titers >800 but did not meet the CSTE case definition for Q fever endocarditis. Conclusions These data summarize a limited set of clinical and epidemiological features of Q fever endocarditis collected through passive surveillance in the United States. Some cases of apparent Q fever endocarditis could not be classified by CSTE laboratory criteria, suggesting that comparison of phase I and phase II titers could be reexamined as a surveillance criterion. Prospective analyses of culture-negative endocarditis are needed to better assess the clinical spectrum and magnitude of Q fever endocarditis in the United States.
Collapse
Affiliation(s)
| | - F Scott Dahlgren
- Rickettsial Zoonoses Branch, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Amy Peterson
- Rickettsial Zoonoses Branch, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Christopher D Paddock
- Rickettsial Zoonoses Branch, Centers for Disease Control and Prevention, Atlanta, Georgia
| |
Collapse
|
34
|
Ananthapavan J, Peterson A, Sacks G. Paying people to lose weight: the effectiveness of financial incentives provided by health insurers for the prevention and management of overweight and obesity - a systematic review. Obes Rev 2018; 19:605-613. [PMID: 29266677 DOI: 10.1111/obr.12657] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2017] [Revised: 10/30/2017] [Accepted: 11/14/2017] [Indexed: 11/29/2022]
Abstract
Curbing the obesity epidemic is likely to require a suite of interventions targeting the obesogenic environment as well as individual behaviour. Evidence suggests that the effectiveness of behaviour modification programmes can be enhanced by financial incentives that immediately reward weight loss behaviour. This systematic review investigated the effectiveness of incentives with a focus on assessing the relative effectiveness of incentives that target different behaviours as well as factors of importance when implementing these programmes in real-world settings (health insurer settings). A narrative review of the academic and grey literature including a variety of study designs was undertaken. Twenty studies met inclusion criteria and were assessed using the Effective Public Health Practice Project Quality Assessment Tool for Quantitative Studies. Results suggest that incentivizing weight loss is effective in the short term while the incentives are in place. There are various incentive designs, and although the relative effectiveness of each of these on weight loss is not clear, it appears that positive incentives increase the uptake into programmes and may reduce dropouts. As with other weight loss initiatives, there is a need to explore ways to maintain weight loss in the longer term - incentives for weight maintenance could play a role.
Collapse
Affiliation(s)
- J Ananthapavan
- Deakin University, Geelong, Australia, Deakin Health Economics, Centre for Population Health Research.,Deakin University, Geelong, Australia, Global Obesity Centre, Centre for Population Health Research
| | - A Peterson
- Deakin University, Geelong, Australia, Deakin Health Economics, Centre for Population Health Research
| | - G Sacks
- Deakin University, Geelong, Australia, Global Obesity Centre, Centre for Population Health Research
| |
Collapse
|
35
|
Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O’Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. J Clin Oncol 2018; 36:884-890. [PMID: 29373071 PMCID: PMC5858523 DOI: 10.1200/jco.2016.71.3495] [Citation(s) in RCA: 310] [Impact Index Per Article: 51.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Purpose Studies suggest that a subset of patients with triple-negative breast cancer (TNBC) have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor. This phase II study evaluated the antitumor activity and safety of enzalutamide in patients with locally advanced or metastatic AR-positive TNBC. Patients and Methods Tumors were tested for AR with an immunohistochemistry assay optimized for breast cancer; nuclear AR staining > 0% was considered positive. Patients received enzalutamide 160 mg once per day until disease progression. The primary end point was clinical benefit rate (CBR) at 16 weeks. Secondary end points included CBR at 24 weeks, progression-free survival, and safety. End points were analyzed in all enrolled patients (the intent-to-treat [ITT] population) and in patients with one or more postbaseline assessment whose tumor expressed ≥ 10% nuclear AR (the evaluable subgroup). Results Of 118 patients enrolled, 78 were evaluable. CBR at 16 weeks was 25% (95% CI, 17% to 33%) in the ITT population and 33% (95% CI, 23% to 45%) in the evaluable subgroup. Median progression-free survival was 2.9 months (95% CI, 1.9 to 3.7 months) in the ITT population and 3.3 months (95% CI, 1.9 to 4.1 months) in the evaluable subgroup. Median overall survival was 12.7 months (95% CI, 8.5 months to not yet reached) in the ITT population and 17.6 months (95% CI, 11.6 months to not yet reached) in the evaluable subgroup. Fatigue was the only treatment-related grade 3 or higher adverse event with an incidence of > 2%. Conclusion Enzalutamide demonstrated clinical activity and was well tolerated in patients with advanced AR-positive TNBC. Adverse events related to enzalutamide were consistent with its known safety profile. This study supports additional development of enzalutamide in advanced TNBC.
Collapse
Affiliation(s)
- Tiffany A. Traina
- Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O’Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d’Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA
| | - Kathy Miller
- Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O’Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d’Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA
| | - Denise A. Yardley
- Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O’Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d’Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA
| | - Janice Eakle
- Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O’Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d’Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA
| | - Lee S. Schwartzberg
- Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O’Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d’Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA
| | - Joyce O’Shaughnessy
- Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O’Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d’Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA
| | - William Gradishar
- Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O’Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d’Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA
| | - Peter Schmid
- Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O’Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d’Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA
| | - Eric Winer
- Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O’Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d’Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA
| | - Catherine Kelly
- Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O’Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d’Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA
| | - Rita Nanda
- Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O’Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d’Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA
| | - Ayca Gucalp
- Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O’Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d’Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA
| | - Ahmad Awada
- Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O’Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d’Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA
| | - Laura Garcia-Estevez
- Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O’Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d’Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA
| | - Maureen E. Trudeau
- Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O’Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d’Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA
| | - Joyce Steinberg
- Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O’Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d’Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA
| | - Hirdesh Uppal
- Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O’Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d’Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA
| | - Iulia Cristina Tudor
- Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O’Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d’Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA
| | - Amy Peterson
- Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O’Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d’Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA
| | - Javier Cortes
- Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O’Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d’Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA
| |
Collapse
|
36
|
Dunville R, Peterson A, Liddon N, Roach M, Coleman K, Dittus P. Sustained Reduction in Chlamydia Infections Following a School-Based Screening: Detroit, 2010-2015. Am J Public Health 2018; 108:231-233. [PMID: 29267064 PMCID: PMC5846582 DOI: 10.2105/ajph.2017.304163] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/28/2017] [Indexed: 11/04/2022]
Abstract
We describe school-based screening events in four Detroit, Michigan public high schools. To examine trends, we analyzed Chlamydia trachomatis data from 2010 to 2015. Prevalence of C. trachomatis decreased significantly (P < .01): from 10.24% to 6.27%. Future school-based screening events may bring about similar results if the program is instituted in a high-prevalence area and can achieve high student participation.
Collapse
Affiliation(s)
- Richard Dunville
- Richard Dunville, Nicole Liddon, and Patricia Dittus are with the Centers for Disease Control and Prevention, Atlanta, GA. Amy Peterson is with the Michigan Department of Health and Human Services, Detroit. Mary Roach is with the Michigan Department of Health and Human Services, Lansing. Kenneth Coleman is with the St. John Providence Health System, Detroit
| | - Amy Peterson
- Richard Dunville, Nicole Liddon, and Patricia Dittus are with the Centers for Disease Control and Prevention, Atlanta, GA. Amy Peterson is with the Michigan Department of Health and Human Services, Detroit. Mary Roach is with the Michigan Department of Health and Human Services, Lansing. Kenneth Coleman is with the St. John Providence Health System, Detroit
| | - Nicole Liddon
- Richard Dunville, Nicole Liddon, and Patricia Dittus are with the Centers for Disease Control and Prevention, Atlanta, GA. Amy Peterson is with the Michigan Department of Health and Human Services, Detroit. Mary Roach is with the Michigan Department of Health and Human Services, Lansing. Kenneth Coleman is with the St. John Providence Health System, Detroit
| | - Mary Roach
- Richard Dunville, Nicole Liddon, and Patricia Dittus are with the Centers for Disease Control and Prevention, Atlanta, GA. Amy Peterson is with the Michigan Department of Health and Human Services, Detroit. Mary Roach is with the Michigan Department of Health and Human Services, Lansing. Kenneth Coleman is with the St. John Providence Health System, Detroit
| | - Kenneth Coleman
- Richard Dunville, Nicole Liddon, and Patricia Dittus are with the Centers for Disease Control and Prevention, Atlanta, GA. Amy Peterson is with the Michigan Department of Health and Human Services, Detroit. Mary Roach is with the Michigan Department of Health and Human Services, Lansing. Kenneth Coleman is with the St. John Providence Health System, Detroit
| | - Patricia Dittus
- Richard Dunville, Nicole Liddon, and Patricia Dittus are with the Centers for Disease Control and Prevention, Atlanta, GA. Amy Peterson is with the Michigan Department of Health and Human Services, Detroit. Mary Roach is with the Michigan Department of Health and Human Services, Lansing. Kenneth Coleman is with the St. John Providence Health System, Detroit
| |
Collapse
|
37
|
Kumar V, Yu J, Phan V, Tudor IC, Peterson A, Uppal H. Androgen Receptor Immunohistochemistry as a Companion Diagnostic Approach to Predict Clinical Response to Enzalutamide in Triple-Negative Breast Cancer. JCO Precis Oncol 2017; 1:1-19. [DOI: 10.1200/po.17.00075] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose The androgen receptor (AR) is increasingly recognized as a potential biomarker for identifying a subset of patients with possible hormonally driven triple-negative breast cancer (TNBC). However, its performance as a companion diagnostic remains elusive. Thus, we evaluated AR expression by immunohistochemistry in patients with advanced TNBC before treatment with the AR inhibitor enzalutamide. Methods We optimized and validated immunohistochemistry assays in breast and prostate cancer cell lines and tissues using two commercial AR monoclonal antibodies (SP107 and AR441). AR expression was then examined in patients with advanced TNBC enrolled in a phase II study of enzalutamide (ClinicalTrials.gov identifier: NCT01889238) on archived or fresh tissue before treatment. Association with clinical response was assessed by sensitivity, specificity, positive predictive value (PPV), drop-out rate, and survival. Results AR expression was detected in 80% and 63% of breast cancer tissue using SP107 and AR441, respectively. SP107 was selected for additional analyses because of its higher sensitivity and robustness. Total AR nuclear staining demonstrated the best accuracy in predicting clinical response (area under receiver operating characteristic curve, 0.72; P = .0001). At a threshold of 10%, 74.6% of patients were AR positive, leading to 30% PPV, 90% sensitivity, and 30% specificity. These patients showed a significantly higher median progression-free survival (hazard ratio, 0.56; 95% CI, 0.36 to 0.88; P = .011) and overall survival (hazard ratio, 0.54; 95% CI, 0.32 to 0.91; P = .019) compared with those with AR-negative (< 10%) TNBC. Conclusion At a threshold of ≥ 10% nuclear expression, the AR was associated with TNBC response to enzalutamide. However, the modest PPV may restrict its clinical application, and additional diagnostic tools may be helpful for improved patient selection.
Collapse
Affiliation(s)
| | - Jianjun Yu
- All authors: Medivation, San Francisco, CA
| | | | | | | | | |
Collapse
|
38
|
Dai W, Peterson A, Kenney T, Burrous H, Montell DJ. Quantitative microscopy of the Drosophila ovary shows multiple niche signals specify progenitor cell fate. Nat Commun 2017; 8:1244. [PMID: 29093440 PMCID: PMC5665863 DOI: 10.1038/s41467-017-01322-9] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2016] [Accepted: 09/09/2017] [Indexed: 01/28/2023] Open
Abstract
Adult stem cells commonly give rise to transit-amplifying progenitors, whose progeny differentiate into distinct cell types. It is unclear if stem cell niche signals coordinate fate decisions within the progenitor pool. Here we use quantitative analysis of Wnt, Hh, and Notch signalling reporters and the cell fate markers Eyes Absent (Eya) and Castor (Cas) to study the effects of hyper-activation and loss of niche signals on progenitor development in the Drosophila ovary. Follicle stem cell (FSC) progeny adopt distinct polar, stalk, and main body cell fates. We show that Wnt signalling transiently inhibits expression of the main body cell fate determinant Eya, and Wnt hyperactivity strongly biases cells towards polar and stalk fates. Hh signalling independently controls the proliferation to differentiation transition. Notch is permissive but not instructive for differentiation of multiple cell types. These findings reveal that multiple niche signals coordinate cell fates and differentiation of progenitor cells.
Collapse
Affiliation(s)
- Wei Dai
- MCDB Department, University of California, Santa Barbara, CA, 93106, USA
| | - Amy Peterson
- MCDB Department, University of California, Santa Barbara, CA, 93106, USA
| | - Thomas Kenney
- MCDB Department, University of California, Santa Barbara, CA, 93106, USA
| | - Haley Burrous
- MCDB Department, University of California, Santa Barbara, CA, 93106, USA
| | - Denise J Montell
- MCDB Department, University of California, Santa Barbara, CA, 93106, USA.
| |
Collapse
|
39
|
Krop I, Abramson V, Colleoni M, Holmes FA, Estevez L, Hart L, Awada A, Zamagni C, Morris P, Schwartzberg L, Chan S, Wheatley D, Guculp A, Biganzoli L, Steinberg J, Gianni L, Trudeau M, Kelly CM, Uppal H, Tudor IC, Peterson A, Winer E, Yardley DA. Abstract P2-08-01: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-08-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- I Krop
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - V Abramson
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - M Colleoni
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - FA Holmes
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Estevez
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Hart
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - A Awada
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - C Zamagni
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - P Morris
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Schwartzberg
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - S Chan
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - D Wheatley
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - A Guculp
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Biganzoli
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - J Steinberg
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Gianni
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - M Trudeau
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - CM Kelly
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - H Uppal
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - IC Tudor
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - A Peterson
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - E Winer
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - DA Yardley
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| |
Collapse
|
40
|
Kim R, Peterson A, Isherwood A, Uppal H, Barlev A. Abstract P5-08-28: Incidence of germline BRCA1- and BRCA2-mutated breast cancer in the US. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-08-28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer is the most common cancer and second leading cause of cancer death among women in the United States (US).1 Inherited mutations in germline breast cancer susceptibility gene 1 and 2 (gBRCAm) are associated with increased risk of developing cancers, including breast cancer.2 No published reports of gBRCAm incidence within an unselected US breast cancer population are available based on a comprehensive literature review (CLR). The main objective of this analysis is to estimate the incidence of gBRCAm breast cancer in the US.
Methods: For this analysis the Surveillance, Epidemiology, and End Results (SEER) Program 18 registries captured incidence of breast cancer by stage, age and gender.3 The size of the US population was based on United Nation's population projections and standardized to the 2010 population.4 Age-specific gBRCAm distribution and gBRCAm-specific hormonal subtype for estrogen-receptor and progesterone-receptor (ER/PR), and human epidermal growth factor receptor-2 (HER2) estimates were determined from a CLR.5-8 Tumor cells negative for ER/PR and HER2 are referred to as triple-negative breast cancer (TNBC).
Results: In 2016, it is projected that approximately 250,000 individuals will be diagnosed with invasive breast cancer (all genders). Median age range of the population with invasive breast cancer is 65-69 years and 99% are females. Majority (72%) of female invasive breast cancer cases are ER/PR+ whereas 11% of cases are TNBC. Corroborating with current publications, gBRCAm is estimated at 5% for individuals less than 50 years old and 1% among all ages. Median age range of the gBRCAm cohort is 40-44 years. After applying currently available gBRCAm specific literature parameters, the majority (55%) of gBRCAm diagnoses are TNBC.
Conclusion: In the US, patients with gBRCAm represent a small proportion (1%) of all breast cancer tissues evaluated. Majority of gBRCAm patients are diagnosed with TNBC (55%) and are younger (median age range 40-44 years) than overall breast cancer population. Age differences noticed in gBRCAm may have been due to disparity in genetic screening practices among breast cancer population in the US rather than a reflection of gBRCAm expressions. These estimates of gBRCAm incidence are driven by limited reports on an unselected population of breast cancer gBRCAm cohort; therefore sensitivity analysis is required to assess the robustness of these estimates.
1. American Cancer Society. Facts and Figures 2016.
2. Miki Y et al. Science. 1994;266:66-71.
3. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973-2013), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission.
4. United Nations Population Division. World Population Prospects, the 2015 Revision. http://esa.un.org/unpd/wpp/.
5. van den Broek et al. Eur J Hum Genet. 2015;23:588-95.
6.Turkovic L et al. BMC Cancer. 2010;10:466.
7. Atchley DP et al. J Clin Oncol. 2008;26:4282-4321.
8. Spurdle AB et al. Breast Cancer Res. 2014;16:3419.
Citation Format: Kim R, Peterson A, Isherwood A, Uppal H, Barlev A. Incidence of germline BRCA1- and BRCA2-mutated breast cancer in the US [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-08-28.
Collapse
Affiliation(s)
- R Kim
- Medivation, Inc., San Francisco, CA; Decision Resources Group, London, United Kingdom
| | - A Peterson
- Medivation, Inc., San Francisco, CA; Decision Resources Group, London, United Kingdom
| | - A Isherwood
- Medivation, Inc., San Francisco, CA; Decision Resources Group, London, United Kingdom
| | - H Uppal
- Medivation, Inc., San Francisco, CA; Decision Resources Group, London, United Kingdom
| | - A Barlev
- Medivation, Inc., San Francisco, CA; Decision Resources Group, London, United Kingdom
| |
Collapse
|
41
|
Litton J, Ettl J, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Yerushalmi R, Woodward N, Goncalves A, Moreno F, Roche H, Im YH, Martin M, Bhattacharya S, Peterson A, Hannah A, Eiermann W, Blum J. Abstract OT2-01-13: A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot2-01-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Cancer cells with deleterious mutations in breast cancer susceptibility genes 1 and 2 (BRCA1/2) are deficient in the DNA double-strand break repair mechanism, rendering them highly dependent on the single-strand break repair pathway, regulated by poly(ADP-ribose) polymerase (PARP). Inhibition of PARP results in synthetic lethality in cells with a BRCA1/2 mutation because of accumulation of irreparable DNA damage; PARP inhibitors have the potential to be selectively toxic for BRCA-mutated cells. In addition to catalytic inhibition, it has been shown that some PARP inhibitors induce PARP trapping at sites of DNA damage. The capacity to trap PARP-DNA complexes varies widely across different PARP inhibitors and is not correlated with PARP catalytic inhibition. Preclinical models have shown trapping PARP on DNA is more potent at inducing cancer cell death than enzymatic inhibition of PARP alone. Talazoparib is a dual-mechanism PARP inhibitor that both inhibits the PARP enzyme and effectively traps PARP on DNA, preventing DNA damage repair and resulting in cell death in BRCA1/2-mutated cells. In preclinical studies, talazoparib at nanomolar concentrations showed the highest efficiency at trapping PARP-DNA complexes relative to other PARP inhibitors. In a previous phase 1/2 clinical study, talazoparib as monotherapy (1 mg once daily) resulted in a 50% response rate and an 86% clinical benefit rate at 24 weeks in 14 patients with a germline BRCA1/2 mutation and advanced breast cancer (aBC).
Methods: This open-label, randomized, 2-arm, international phase 3 trial (EMBRACA)
compares the efficacy and safety of talazoparib with protocol-specific physician's choice (capecitabine, eribulin, gemcitabine or vinorelbine) in patients with aBC. The primary objective is progression-free survival by central imaging. Secondary objectives are objective response rate, overall survival, safety and pharmacokinetics of talazoparib. Exploratory objectives include health-related quality of life measurements and biomarker research in blood and tumor samples that may permit characterization of mechanisms involved in tumor sensitivity and resistance to talazoparib. Key patient eligibility criteria include aged ≥18 years with histologically/cytologically confirmed breast cancer; locally advanced and/or metastatic disease appropriate for systemic single-agent cytotoxic chemotherapy; deleterious or pathogenic germline BRCA1/2 mutations by central laboratory; ≤3 prior cytotoxic chemotherapy regimens for advanced disease (prior platinum is allowed provided patients did not relapse within 6 months in the adjuvant setting or did not progress on platinum therapy); prior treatment with a taxane and/or anthracycline unless medically contraindicated; and ECOG performance status ≤2. Patients (N=429) will be randomized 2:1 to receive either talazoparib capsules (1 mg/day, 21-day cycles) or physician's choice treatment. This trial is currently enrolling patients from the USA, Europe, Israel, Ukraine, Russia, Korea, Australia, Taiwan and Brazil (NCT01945775).
This study is funded by Medivation, Inc.
Citation Format: Litton J, Ettl J, Hurvitz SA, Mina LA, Rugo HS, Lee K-H, Yerushalmi R, Woodward N, Goncalves A, Moreno F, Roche H, Im Y-H, Martin M, Bhattacharya S, Peterson A, Hannah A, Eiermann W, Blum J. A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT2-01-13.
Collapse
Affiliation(s)
- J Litton
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - J Ettl
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - SA Hurvitz
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - LA Mina
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - HS Rugo
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - K-H Lee
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - R Yerushalmi
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - N Woodward
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - A Goncalves
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - F Moreno
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - H Roche
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - Y-H Im
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - M Martin
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - S Bhattacharya
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - A Peterson
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - A Hannah
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - W Eiermann
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| | - J Blum
- MD Anderson Cancer Center, Houston, TX; Technische Universität München, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Indiana University School of Medicine, Indianapolis, IN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Seoul National University Hospital, Seoul, Korea; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Mater Cancer Care Centre-Mater Health Services, South Brisbane, Australia; Institut Paoli-Calmettes, Marseille, France; Hospital Clínico San Carlos, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Korea; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medivation, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Munich, Germany; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
| |
Collapse
|
42
|
Abstract
Abstract
Background: BRCA1 and BRCA2 functions are essential for the DNA double-strand break repair process in living cells with DNA damages. Therefore, germline pathogenic mutations in BRCA1/2 increases the risk of developing cancer.1, 2Poly(ADP-ribose) polymerase (PARP) enzymes are proteins responsible for DNA single-strand break repair. Persistent inhibition of PARP-dependent DNA repair in BRCA-deficient breast cancer cells leads to increased DNA damages resulting in cancer cell death. Talazoparib is a novel and potent, orally bioavailable, small molecule PARP inhibitor. Talazoparib's dual mechanism of action inhibits PARP enzyme activity and effectively traps PARP on DNA, preventing DNA repair, resulting in cell death in BRCA1/2-mutated cells.3 In tissue culture studies, talazoparib is more potent at trapping PARP on DNA to induce cancer cell death compared to other PARP inhibitors.4 Previous studies have demonstrated talazoparib inhibited growth in tumors harboring BRCA1/2 gene mutations. In the MX-1 breast cancer model with BRCA1-deficiency, talazoparib inhibited cell growth in vitro and induced regression in solid mouse xenografts.5 Here, we demonstrate antitumor effects of talazoparib monotherapy in a panel of breast cancer cells and patient-derived breast cancer models with pathologic BRCA1/2 mutations.
Method: A panel of human breast cancer cell lines was treated with talazoparib to determine its cytotoxic effects. BRCA1/2 mutations status was correlated to talazoparib cytotoxic effects. At the molecular level, BRCA1/2-mutant and wild type breast cancer cell lines were treated with dose-escalating talazoparib to also assess the relationship between PARP-DNA trapping complex formation and treatment response. Patient-derived breast cancer xenograft models were used to assess talazoparib monotherapy on tumorigenesis. Immunohistochemistry assays were performed to determine Ki-67, gH2AX and caspase 3 marker expression following talazoparib treatment.
Results: Cytotoxicity was observed in 50% (7/14) cell lines at IC50 values that are achieved in the clinic. BRCA1/2 alterations were detected in 21.4% (3/14) of cell lines sensitive to talazoparib treatment. In 14 patient-derived breast cancer xenograft models selected for this study, 57.1% (8/14) responded to talazoparib monotherapy. Of these, 35.7% had mutations in the BRCA1 (28.6%) and BRCA2 (7.1%) genes. Stable disease was observed in 14.2% (2/14). One stable model had BRCA1 mutations. Tumor regression was observed in 42.8% (6/14) of the models treated with talazoparib monotherapy. Importantly, 66.7% (4/6) of patient-derived breast cancer models that regressed on talazoparib monotherapy had mutations in BRCA1/2 genes.
Conclusions: Cytotoxicity was observed with talazoparib monotherapy in breast cancer cell lines and in patient-derived xenograft tumor models harboring BRCA1 or BRCA2 mutations. Our data demonstrate therapeutic potential of talazoparib monotherapy in breast cancer associated with pathologic BRCA1/2 mutations.
1.Couch FJ et al. J Clin Oncol. 2015;33:304-11.
2. Petrucelli N et al. Genet Med. 2010;12:245-59.
3. Wang B et al. J Med Chem. 2016;59:335-57.
4. Murai J et al. Mol Cancer Ther. 2014;13:433-43.
5. Shen Y et al. Clin Cancer Res. 2013;19:5003-15.
Citation Format: Phan VT, Protter AA, Peterson A, Uppal H. Talazoparib antitumor effects in BRCA-deficient breast cancer models [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-06-01.
Collapse
Affiliation(s)
- VT Phan
- Medivation, Inc., San Francisco, CA
| | | | | | - H Uppal
- Medivation, Inc., San Francisco, CA
| |
Collapse
|
43
|
Krop I, Cortes J, Miller K, Huizing MT, Provencher L, Gianni L, Chan S, Trudeau M, Steinberg J, Sugg J, Liosatos M, Paton VE, Peterson A, Wardley A. Abstract P4-22-08: A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-22-08] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:Androgen receptor (AR) expression has been observed in up to 77% of human epidermal growth factor receptor 2–positive (HER2+) breast cancer (BC).References:1 Enzalutamide (ENZA) is a potent AR inhibitor approved for patients (pts) with metastatic castration-resistant prostate cancer. In vitro, ENZA enhances antitumor activity of trastuzumab in HER2+ AR+ cell lines and inhibits proliferation in trastuzumab-resistant HER2+ cell lines.2
Methods:Pts with metastatic or locally advanced BC that was HER2+ AR+ by local or central laboratory assessment were enrolled in a single-arm, Simon 2-stage phase 2 study (NCT02091960). Key eligibility criteria included availability of a tissue sample, presence of measurable or evaluable disease per RECIST v1.1, progression on prior trastuzumab and ≥1 prior line of anti-HER2 therapy as the most recent regimen. Brain metastases and history of seizure were exclusionary. Evaluable pts were those with centrally confirmed nuclear AR expression≥10% by immunohistochemistry who received ≥1 dose of ENZA and had ≥1 postbaseline tumor assessment. Pts received ENZA 160 mg daily and trastuzumab 6 mg/kg every 21 days until disease progression. The primary objective was clinical benefit rate at 24 weeks (CBR24), defined as complete or partial response (CR or PR) or stable disease (SD) for ≥24 weeks in evaluable pts. Additional endpoints included safety and progression-free survival (PFS). CBR24 in ≥3 of 21 evaluable pts was required to continue to stage 2 and enrollment of up to 66 evaluable pts total. This design yields a 1-sided type 1 error of 5% and 90% power when the true response is 25%.
Results:Here we present results from stage 1 (data cutoff: Mar 23, 2016), with 22 evaluable pts enrolled (pts 21 and 22 enrolled simultaneously); 18 had received ≥4 prior lines of therapy. Median duration of ENZA exposure was 144 days (range, 22-495), mean number of complete trastuzumab infusions was 6.5. CBR24 was 27.3% (95% confidence interval [CI], 10.7-50.2); 2 confirmed PR and 4 SD ≥24 weeks. Median PFS was 108 days (95% CI, 56-144). All pts experienced ≥1 adverse event (AE) any grade; 5 pts experienced AEs grade ≥3. ENZA-related AEs were reported in 16 pts (72.7%), the most common (in ≥10% of pts) were fatigue (22.7%), nausea (18.2%), diarrhea (13.6%) and arthralgia (13.6%). Serious AEs were reported in 6 pts (27.3%; 2 each of infection and back pain, 1 each of abdominal pain, nausea, vomiting, pyrexia, urinary retention and pulmonary edema). Two pts discontinued due to drug-related AEs: 1 related to both drugs, 1 related to trastuzumab. One on-study death from pulmonary edema was reported, which was not considered related to either drug.
Conclusion:Stage 1 met its primary objective. No new safety signals were identified, and the safety profile in this study was similar to that in men with prostate cancer and women with other BC subtypes treated with ENZA. These results are encouraging for a heavily pretreated population with advanced HER2+ AR+ BC. Enrollment in stage 2 continues with the combination of ENZA and trastuzumab.
1. Micello D et al. Virchows Arch. 2010;457:467-476.
2. Richer J. Presented at AACR Advances in Breast Cancer, San Diego, CA, 2013.
Citation Format: Krop I, Cortes J, Miller K, Huizing MT, Provencher L, Gianni L, Chan S, Trudeau M, Steinberg J, Sugg J, Liosatos M, Paton VE, Peterson A, Wardley A. A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-22-08.
Collapse
Affiliation(s)
- I Krop
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - J Cortes
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - K Miller
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - MT Huizing
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - L Provencher
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - L Gianni
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - S Chan
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - M Trudeau
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - J Steinberg
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - J Sugg
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - M Liosatos
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - VE Paton
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - A Peterson
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| | - A Wardley
- Dana-Farber Cancer Institute, Boston, MA; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Indiana University Simon Cancer Center, Indianapolis, IN; Antwerp University Hospital Edegem, Antwerp, Belgium; Hôpital du Saint-Sacrement du CHU de Quebec, QC, Canada; Ospedale San Raffaele, Milan, Italy; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Sunnybrook Health Sciences Centre, Toronto, Canada; Astellas Pharma, Inc., Northbrook, IL; Medivation, Inc., San Francisco, CA; The Christie NIHR/CRUK Clinical Research Facility, Manchester, United Kingdom
| |
Collapse
|
44
|
Peterson A, Brown A, Savage A, Dempsey A. Factors associated with bleeding evaluation and early discontinuation among etonogestrel contraceptive implant users. Contraception 2016. [DOI: 10.1016/j.contraception.2016.07.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
45
|
Chatham-Stephens K, Taylor E, Chang A, Peterson A, Daniel J, Martin C, Deuster P, Noe R, Kieszak S, Schier J, Klontz K, Lewis L. Hepatotoxicity associated with weight loss or sports dietary supplements, including OxyELITE Pro™ - United States, 2013. Drug Test Anal 2016; 9:68-74. [PMID: 27367536 DOI: 10.1002/dta.2036] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2015] [Revised: 06/25/2016] [Accepted: 06/26/2016] [Indexed: 12/14/2022]
Abstract
In September 2013, the Hawaii Department of Health (HDOH) was notified of seven adults who developed acute hepatitis after taking OxyELITE Pro™, a weight loss and sports dietary supplement. CDC assisted HDOH with their investigation, then conducted case-finding outside of Hawaii with FDA and the Department of Defense (DoD). We defined cases as acute hepatitis of unknown etiology that occurred from April 1, 2013, through December 5, 2013, following exposure to a weight loss or muscle-building dietary supplement, such as OxyELITE Pro™. We conducted case-finding through multiple sources, including data from poison centers (National Poison Data System [NPDS]) and FDA MedWatch. We identified 40 case-patients in 23 states and two military bases with acute hepatitis of unknown etiology and exposure to a weight loss or muscle building dietary supplement. Of 35 case-patients who reported their race, 15 (42.9%) reported white and 9 (25.7%) reported Asian. Commonly reported symptoms included jaundice, fatigue, and dark urine. Twenty-five (62.5%) case-patients reported taking OxyELITE Pro™. Of these 25 patients, 17 of 22 (77.3%) with available data were hospitalized and 1 received a liver transplant. NPDS and FDA MedWatch each captured seven (17.5%) case-patients. Improving the ability to search surveillance systems like NPDS and FDA MedWatch for individual and grouped dietary supplements, as well as coordinating case-finding with DoD, may benefit ongoing surveillance efforts and future outbreak responses involving adverse health effects from dietary supplements. This investigation highlights opportunities and challenges in using multiple sources to identify cases of suspected supplement associated adverse events. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
Collapse
Affiliation(s)
- Kevin Chatham-Stephens
- EIS officer, 1600 Clifton Road NE MS C-09, Atlanta, GA.,Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention
| | - Ethel Taylor
- Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention
| | - Arthur Chang
- Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention
| | - Amy Peterson
- Division of Integrated Biosurveillance, Armed Forces Health Surveillance Center
| | - Johnni Daniel
- Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention
| | - Colleen Martin
- Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention
| | - Patricia Deuster
- Department of Military and Emergency Medicine, Uniformed Services University
| | - Rebecca Noe
- Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention
| | - Stephanie Kieszak
- Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention
| | - Josh Schier
- Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention
| | - Karl Klontz
- Office of Analytics and Outreach, Center for Food Safety and Applied Nutrition, Food and Drug Administration
| | - Lauren Lewis
- Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention
| |
Collapse
|
46
|
Abstract
The sudden emergence and worldwide adoption of CRISPR gene-editing technology confronts humanity with unprecedented opportunities and choices. CRISPR's transformative impact on our future understanding of biology, along with its potential to unleash control over the most fundamental of biological processes, is predictable by already achieved applications. Although its origin, composition, and function were revealed only recently, close to 3000 CRISPR-based publications have appeared including insightful and diversely focused reviews referenced here. Adding further to scientific and public awareness, a recent symposium addressed the ethical implications of interfacing CRISPR technology and human biology. However, the magnitude of CRISPR's rapidly emerging power mandates its broadest assessment. Only with the participation of a diverse and informed community can the most effective and humanity-positive CRISPR applications be defined. This brief review is aimed at those with little previous exposure to the CRISPR revolution. The molecules that constitute CRISPR's core components and their functional organization are described along with how the mechanism has been harnessed to edit genome structure and modulate gene function. Additionally, a glimpse into CRISPR's potential to unleash genetic changes with far-reaching consequences is presented.
Collapse
Affiliation(s)
- A Peterson
- Laboratory of Developmental Biology, Departments of Oncology, Human Genetics, Neurology & Neurosurgery, McGill University, Montreal, QC, Canada
| |
Collapse
|
47
|
Mendez M, Cone E, Lavien G, Zaid U, Peterson A, Lentz A. 047 Recovery of Glans Sensation Following Combined Dorsal and Ventral Onlay with a Glans Splitting Technique for Strictures of the Fossa Navicularis. J Sex Med 2016. [DOI: 10.1016/j.jsxm.2016.02.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
48
|
Peterson A, Hennemeyer C. Denver peritoneo-venous shunt (DPVS): an essential tool in the management of malignant ascites. J Vasc Interv Radiol 2016. [DOI: 10.1016/j.jvir.2015.12.634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
49
|
Adamczyk L, Adkins JK, Agakishiev G, Aggarwal MM, Ahammed Z, Alekseev I, Aparin A, Arkhipkin D, Aschenauer EC, Averichev GS, Bairathi V, Banerjee A, Bellwied R, Bhasin A, Bhati AK, Bhattarai P, Bielcik J, Bielcikova J, Bland LC, Bordyuzhin IG, Bouchet J, Brandin AV, Bunzarov I, Butterworth J, Caines H, Calderón de la Barca Sánchez M, Campbell JM, Cebra D, Cervantes MC, Chakaberia I, Chaloupka P, Chang Z, Chattopadhyay S, Chen JH, Chen X, Cheng J, Cherney M, Christie W, Contin G, Crawford HJ, Das S, De Silva LC, Debbe RR, Dedovich TG, Deng J, Derevschikov AA, di Ruzza B, Didenko L, Dilks C, Dong X, Drachenberg JL, Draper JE, Du CM, Dunkelberger LE, Dunlop JC, Efimov LG, Engelage J, Eppley G, Esha R, Evdokimov O, Eyser O, Fatemi R, Fazio S, Federic P, Fedorisin J, Feng Z, Filip P, Fisyak Y, Flores CE, Fulek L, Gagliardi CA, Garand D, Geurts F, Gibson A, Girard M, Greiner L, Grosnick D, Gunarathne DS, Guo Y, Gupta S, Gupta A, Guryn W, Hamad A, Hamed A, Haque R, Harris JW, He L, Heppelmann S, Heppelmann S, Hirsch A, Hoffmann GW, Hofman DJ, Horvat S, Huang X, Huang B, Huang HZ, Huck P, Humanic TJ, Igo G, Jacobs WW, Jang H, Jiang K, Judd EG, Kabana S, Kalinkin D, Kang K, Kauder K, Ke HW, Keane D, Kechechyan A, Khan ZH, Kikoła DP, Kisel I, Kisiel A, Kochenda L, Koetke DD, Kollegger T, Kosarzewski LK, Kraishan AF, Kravtsov P, Krueger K, Kulakov I, Kumar L, Kycia RA, Lamont MAC, Landgraf JM, Landry KD, Lauret J, Lebedev A, Lednicky R, Lee JH, Li ZM, Li W, Li X, Li X, Li C, Li Y, Lisa MA, Liu F, Ljubicic T, Llope WJ, Lomnitz M, Longacre RS, Luo X, Ma YG, Ma GL, Ma L, Ma R, Magdy N, Majka R, Manion A, Margetis S, Markert C, Masui H, Matis HS, McDonald D, Meehan K, Minaev NG, Mioduszewski S, Mishra D, Mohanty B, Mondal MM, Morozov DA, Mustafa MK, Nandi BK, Nasim M, Nayak TK, Nigmatkulov G, Nogach LV, Noh SY, Novak J, Nurushev SB, Odyniec G, Ogawa A, Oh K, Okorokov V, Olvitt D, Page BS, Pak R, Pan YX, Pandit Y, Panebratsev Y, Pawlik B, Pei H, Perkins C, Peterson A, Pile P, Planinic M, Pluta J, Poljak N, Poniatowska K, Porter J, Posik M, Poskanzer AM, Putschke J, Qiu H, Quintero A, Ramachandran S, Raniwala R, Raniwala S, Ray RL, Ritter HG, Roberts JB, Rogachevskiy OV, Romero JL, Roy A, Ruan L, Rusnak J, Rusnakova O, Sahoo NR, Sahu PK, Sakrejda I, Salur S, Sandweiss J, Sarkar A, Schambach J, Scharenberg RP, Schmah AM, Schmidke WB, Schmitz N, Seger J, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao M, Sharma B, Sharma MK, Shen WQ, Shi SS, Shou QY, Sichtermann EP, Sikora R, Simko M, Singha S, Skoby MJ, Smirnov D, Smirnov N, Song L, Sorensen P, Spinka HM, Srivastava B, Stanislaus TDS, Stepanov M, Stock R, Strikhanov M, Stringfellow B, Sumbera M, Summa B, Sun X, Sun XM, Sun Y, Sun Z, Surrow B, Svirida N, Szelezniak MA, Tang AH, Tang Z, Tarnowsky T, Tawfik A, Thomas JH, Timmins AR, Tlusty D, Tokarev M, Trentalange S, Tribble RE, Tribedy P, Tripathy SK, Trzeciak BA, Tsai OD, Ullrich T, Underwood DG, Upsal I, Van Buren G, van Nieuwenhuizen G, Vandenbroucke M, Varma R, Vasiliev AN, Vertesi R, Videbæk F, Viyogi YP, Vokal S, Voloshin SA, Vossen A, Wang Y, Wang G, Wang JS, Wang H, Wang Y, Wang F, Webb JC, Webb G, Wen L, Westfall GD, Wieman H, Wissink SW, Witt R, Wu YF, Wu Y, Xiao ZG, Xie W, Xin K, Xu N, Xu Z, Xu QH, Xu YF, Xu H, Yang Q, Yang Y, Yang Y, Yang S, Yang C, Ye Z, Yepes P, Yi L, Yip K, Yoo IK, Yu N, Zbroszczyk H, Zha W, Zhang Z, Zhang Y, Zhang JB, Zhang J, Zhang S, Zhang J, Zhang XP, Zhao J, Zhong C, Zhou L, Zhu X, Zoulkarneeva Y, Zyzak M. Centrality and Transverse Momentum Dependence of Elliptic Flow of Multistrange Hadrons and ϕ Meson in Au+Au Collisions at √[sNN]=200 GeV. Phys Rev Lett 2016; 116:062301. [PMID: 26918982 DOI: 10.1103/physrevlett.116.062301] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/19/2015] [Indexed: 06/05/2023]
Abstract
We present high precision measurements of elliptic flow near midrapidity (|y|<1.0) for multistrange hadrons and ϕ meson as a function of centrality and transverse momentum in Au+Au collisions at center of mass energy √[sNN]=200 GeV. We observe that the transverse momentum dependence of ϕ and Ω v2 is similar to that of π and p, respectively, which may indicate that the heavier strange quark flows as strongly as the lighter up and down quarks. This observation constitutes a clear piece of evidence for the development of partonic collectivity in heavy-ion collisions at the top RHIC energy. Number of constituent quark scaling is found to hold within statistical uncertainty for both 0%-30% and 30%-80% collision centrality. There is an indication of the breakdown of previously observed mass ordering between ϕ and proton v2 at low transverse momentum in the 0%-30% centrality range, possibly indicating late hadronic interactions affecting the proton v2.
Collapse
Affiliation(s)
- L Adamczyk
- AGH University of Science and Technology, Cracow 30-059, Poland
| | - J K Adkins
- University of Kentucky, Lexington, Kentucky 40506-0055, USA
| | - G Agakishiev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | | | - Z Ahammed
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - I Alekseev
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - A Aparin
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - D Arkhipkin
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - E C Aschenauer
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G S Averichev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - V Bairathi
- National Institute of Science Education and Research, Jatni 752050, Odisha, India
| | - A Banerjee
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - R Bellwied
- University of Houston, Houston, Texas 77204, USA
| | - A Bhasin
- University of Jammu, Jammu 180001, India
| | - A K Bhati
- Panjab University, Chandigarh 160014, India
| | - P Bhattarai
- University of Texas, Austin, Texas 78712, USA
| | - J Bielcik
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - J Bielcikova
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - L C Bland
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - I G Bordyuzhin
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - J Bouchet
- Kent State University, Kent, Ohio 44242, USA
| | - A V Brandin
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | - I Bunzarov
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | | | - H Caines
- Yale University, New Haven, Connecticut 06520, USA
| | | | - J M Campbell
- Ohio State University, Columbus, Ohio 43210, USA
| | - D Cebra
- University of California, Davis, California 95616, USA
| | - M C Cervantes
- Texas A&M University, College Station, Texas 77843, USA
| | - I Chakaberia
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - P Chaloupka
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - Z Chang
- Texas A&M University, College Station, Texas 77843, USA
| | | | - J H Chen
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - X Chen
- Institute of Modern Physics, Lanzhou 730000, China
| | - J Cheng
- Tsinghua University, Beijing 100084, China
| | - M Cherney
- Creighton University, Omaha, Nebraska 68178, USA
| | - W Christie
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G Contin
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - H J Crawford
- University of California, Berkeley, California 94720, USA
| | - S Das
- Institute of Physics, Bhubaneswar 751005, India
| | - L C De Silva
- Creighton University, Omaha, Nebraska 68178, USA
| | - R R Debbe
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - T G Dedovich
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - J Deng
- Shandong University, Jinan, Shandong 250100, China
| | | | - B di Ruzza
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L Didenko
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C Dilks
- Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - X Dong
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | | | - J E Draper
- University of California, Davis, California 95616, USA
| | - C M Du
- Institute of Modern Physics, Lanzhou 730000, China
| | | | - J C Dunlop
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L G Efimov
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - J Engelage
- University of California, Berkeley, California 94720, USA
| | - G Eppley
- Rice University, Houston, Texas 77251, USA
| | - R Esha
- University of California, Los Angeles, California 90095, USA
| | - O Evdokimov
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - O Eyser
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R Fatemi
- University of Kentucky, Lexington, Kentucky 40506-0055, USA
| | - S Fazio
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - P Federic
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - J Fedorisin
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - Z Feng
- Central China Normal University (HZNU), Wuhan 430079, China
| | - P Filip
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - Y Fisyak
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C E Flores
- University of California, Davis, California 95616, USA
| | - L Fulek
- AGH University of Science and Technology, Cracow 30-059, Poland
| | - C A Gagliardi
- Texas A&M University, College Station, Texas 77843, USA
| | - D Garand
- Purdue University, West Lafayette, Indiana 47907, USA
| | - F Geurts
- Rice University, Houston, Texas 77251, USA
| | - A Gibson
- Valparaiso University, Valparaiso, Indiana 46383, USA
| | - M Girard
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - L Greiner
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - D Grosnick
- Valparaiso University, Valparaiso, Indiana 46383, USA
| | - D S Gunarathne
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - Y Guo
- University of Science and Technology of China, Hefei 230026, China
| | - S Gupta
- University of Jammu, Jammu 180001, India
| | - A Gupta
- University of Jammu, Jammu 180001, India
| | - W Guryn
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Hamad
- Kent State University, Kent, Ohio 44242, USA
| | - A Hamed
- Texas A&M University, College Station, Texas 77843, USA
| | - R Haque
- National Institute of Science Education and Research, Jatni 752050, Odisha, India
| | - J W Harris
- Yale University, New Haven, Connecticut 06520, USA
| | - L He
- Purdue University, West Lafayette, Indiana 47907, USA
| | - S Heppelmann
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - S Heppelmann
- Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - A Hirsch
- Purdue University, West Lafayette, Indiana 47907, USA
| | | | - D J Hofman
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - S Horvat
- Yale University, New Haven, Connecticut 06520, USA
| | - X Huang
- Tsinghua University, Beijing 100084, China
| | - B Huang
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - H Z Huang
- University of California, Los Angeles, California 90095, USA
| | - P Huck
- Central China Normal University (HZNU), Wuhan 430079, China
| | - T J Humanic
- Ohio State University, Columbus, Ohio 43210, USA
| | - G Igo
- University of California, Los Angeles, California 90095, USA
| | - W W Jacobs
- Indiana University, Bloomington, Indiana 47408, USA
| | - H Jang
- Korea Institute of Science and Technology Information, Daejeon 305-701, Korea
| | - K Jiang
- University of Science and Technology of China, Hefei 230026, China
| | - E G Judd
- University of California, Berkeley, California 94720, USA
| | - S Kabana
- Kent State University, Kent, Ohio 44242, USA
| | - D Kalinkin
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - K Kang
- Tsinghua University, Beijing 100084, China
| | - K Kauder
- Wayne State University, Detroit, Michigan 48201, USA
| | - H W Ke
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D Keane
- Kent State University, Kent, Ohio 44242, USA
| | - A Kechechyan
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - Z H Khan
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - D P Kikoła
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - I Kisel
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| | - A Kisiel
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - L Kochenda
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | - D D Koetke
- Valparaiso University, Valparaiso, Indiana 46383, USA
| | - T Kollegger
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| | | | - A F Kraishan
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - P Kravtsov
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | - K Krueger
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - I Kulakov
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| | - L Kumar
- Panjab University, Chandigarh 160014, India
| | - R A Kycia
- Institute of Nuclear Physics PAN, Cracow 31-342, Poland
| | - M A C Lamont
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J M Landgraf
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - K D Landry
- University of California, Los Angeles, California 90095, USA
| | - J Lauret
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Lebedev
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R Lednicky
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - J H Lee
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Z M Li
- Central China Normal University (HZNU), Wuhan 430079, China
| | - W Li
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - X Li
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - X Li
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - C Li
- University of Science and Technology of China, Hefei 230026, China
| | - Y Li
- Tsinghua University, Beijing 100084, China
| | - M A Lisa
- Ohio State University, Columbus, Ohio 43210, USA
| | - F Liu
- Central China Normal University (HZNU), Wuhan 430079, China
| | - T Ljubicic
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - W J Llope
- Wayne State University, Detroit, Michigan 48201, USA
| | - M Lomnitz
- Kent State University, Kent, Ohio 44242, USA
| | - R S Longacre
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - X Luo
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Y G Ma
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - G L Ma
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - L Ma
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - R Ma
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - N Magdy
- World Laboratory for Cosmology and Particle Physics (WLCAPP), Cairo 11571, Egypt
| | - R Majka
- Yale University, New Haven, Connecticut 06520, USA
| | - A Manion
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S Margetis
- Kent State University, Kent, Ohio 44242, USA
| | - C Markert
- University of Texas, Austin, Texas 78712, USA
| | - H Masui
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - H S Matis
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - D McDonald
- University of Houston, Houston, Texas 77204, USA
| | - K Meehan
- University of California, Davis, California 95616, USA
| | - N G Minaev
- Institute of High Energy Physics, Protvino 142281, Russia
| | | | - D Mishra
- National Institute of Science Education and Research, Jatni 752050, Odisha, India
| | - B Mohanty
- National Institute of Science Education and Research, Jatni 752050, Odisha, India
| | - M M Mondal
- Texas A&M University, College Station, Texas 77843, USA
| | - D A Morozov
- Institute of High Energy Physics, Protvino 142281, Russia
| | - M K Mustafa
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - B K Nandi
- Indian Institute of Technology, Mumbai 400076, India
| | - Md Nasim
- University of California, Los Angeles, California 90095, USA
| | - T K Nayak
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - G Nigmatkulov
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | - L V Nogach
- Institute of High Energy Physics, Protvino 142281, Russia
| | - S Y Noh
- Korea Institute of Science and Technology Information, Daejeon 305-701, Korea
| | - J Novak
- Michigan State University, East Lansing, Michigan 48824, USA
| | - S B Nurushev
- Institute of High Energy Physics, Protvino 142281, Russia
| | - G Odyniec
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A Ogawa
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - K Oh
- Pusan National University, Pusan 609735, Republic of Korea
| | - V Okorokov
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | - D Olvitt
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - B S Page
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R Pak
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Y X Pan
- University of California, Los Angeles, California 90095, USA
| | - Y Pandit
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - Y Panebratsev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - B Pawlik
- Institute of Nuclear Physics PAN, Cracow 31-342, Poland
| | - H Pei
- Central China Normal University (HZNU), Wuhan 430079, China
| | - C Perkins
- University of California, Berkeley, California 94720, USA
| | - A Peterson
- Ohio State University, Columbus, Ohio 43210, USA
| | - P Pile
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M Planinic
- University of Zagreb, Zagreb HR-10002, Croatia
| | - J Pluta
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - N Poljak
- University of Zagreb, Zagreb HR-10002, Croatia
| | - K Poniatowska
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - J Porter
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - M Posik
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - A M Poskanzer
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - J Putschke
- Wayne State University, Detroit, Michigan 48201, USA
| | - H Qiu
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A Quintero
- Kent State University, Kent, Ohio 44242, USA
| | - S Ramachandran
- University of Kentucky, Lexington, Kentucky 40506-0055, USA
| | - R Raniwala
- University of Rajasthan, Jaipur 302004, India
| | - S Raniwala
- University of Rajasthan, Jaipur 302004, India
| | - R L Ray
- University of Texas, Austin, Texas 78712, USA
| | - H G Ritter
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | | | | | - J L Romero
- University of California, Davis, California 95616, USA
| | - A Roy
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - L Ruan
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Rusnak
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - O Rusnakova
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - N R Sahoo
- Texas A&M University, College Station, Texas 77843, USA
| | - P K Sahu
- Institute of Physics, Bhubaneswar 751005, India
| | - I Sakrejda
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S Salur
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - J Sandweiss
- Yale University, New Haven, Connecticut 06520, USA
| | - A Sarkar
- Indian Institute of Technology, Mumbai 400076, India
| | - J Schambach
- University of Texas, Austin, Texas 78712, USA
| | | | - A M Schmah
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - W B Schmidke
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - N Schmitz
- Max-Planck-Institut fur Physik, Munich 80805, Germany
| | - J Seger
- Creighton University, Omaha, Nebraska 68178, USA
| | - P Seyboth
- Max-Planck-Institut fur Physik, Munich 80805, Germany
| | - N Shah
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - E Shahaliev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | | | - M Shao
- University of Science and Technology of China, Hefei 230026, China
| | - B Sharma
- Panjab University, Chandigarh 160014, India
| | - M K Sharma
- University of Jammu, Jammu 180001, India
| | - W Q Shen
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - S S Shi
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Q Y Shou
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - E P Sichtermann
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - R Sikora
- AGH University of Science and Technology, Cracow 30-059, Poland
| | - M Simko
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - S Singha
- Kent State University, Kent, Ohio 44242, USA
| | - M J Skoby
- Indiana University, Bloomington, Indiana 47408, USA
| | - D Smirnov
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - N Smirnov
- Yale University, New Haven, Connecticut 06520, USA
| | - L Song
- University of Houston, Houston, Texas 77204, USA
| | - P Sorensen
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - H M Spinka
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - B Srivastava
- Purdue University, West Lafayette, Indiana 47907, USA
| | | | - M Stepanov
- Purdue University, West Lafayette, Indiana 47907, USA
| | - R Stock
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| | - M Strikhanov
- Moscow Engineering Physics Institute, Moscow 115409, Russia
| | | | - M Sumbera
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - B Summa
- Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - X Sun
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - X M Sun
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Y Sun
- University of Science and Technology of China, Hefei 230026, China
| | - Z Sun
- Institute of Modern Physics, Lanzhou 730000, China
| | - B Surrow
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - N Svirida
- Alikhanov Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - M A Szelezniak
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A H Tang
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Z Tang
- University of Science and Technology of China, Hefei 230026, China
| | - T Tarnowsky
- Michigan State University, East Lansing, Michigan 48824, USA
| | - A Tawfik
- World Laboratory for Cosmology and Particle Physics (WLCAPP), Cairo 11571, Egypt
| | - J H Thomas
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A R Timmins
- University of Houston, Houston, Texas 77204, USA
| | - D Tlusty
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - M Tokarev
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - S Trentalange
- University of California, Los Angeles, California 90095, USA
| | - R E Tribble
- Texas A&M University, College Station, Texas 77843, USA
| | - P Tribedy
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | | | - B A Trzeciak
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - O D Tsai
- University of California, Los Angeles, California 90095, USA
| | - T Ullrich
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D G Underwood
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - I Upsal
- Ohio State University, Columbus, Ohio 43210, USA
| | - G Van Buren
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | | | | | - R Varma
- Indian Institute of Technology, Mumbai 400076, India
| | - A N Vasiliev
- Institute of High Energy Physics, Protvino 142281, Russia
| | - R Vertesi
- Nuclear Physics Institute AS CR, 250 68 Řež/Prague, Czech Republic
| | - F Videbæk
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Y P Viyogi
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - S Vokal
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - S A Voloshin
- Wayne State University, Detroit, Michigan 48201, USA
| | - A Vossen
- Indiana University, Bloomington, Indiana 47408, USA
| | - Y Wang
- Tsinghua University, Beijing 100084, China
| | - G Wang
- University of California, Los Angeles, California 90095, USA
| | - J S Wang
- Institute of Modern Physics, Lanzhou 730000, China
| | - H Wang
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Y Wang
- Central China Normal University (HZNU), Wuhan 430079, China
| | - F Wang
- Purdue University, West Lafayette, Indiana 47907, USA
| | - J C Webb
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G Webb
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L Wen
- University of California, Los Angeles, California 90095, USA
| | - G D Westfall
- Michigan State University, East Lansing, Michigan 48824, USA
| | - H Wieman
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S W Wissink
- Indiana University, Bloomington, Indiana 47408, USA
| | - R Witt
- United States Naval Academy, Annapolis, Maryland 21402, USA
| | - Y F Wu
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Y Wu
- Kent State University, Kent, Ohio 44242, USA
| | - Z G Xiao
- Tsinghua University, Beijing 100084, China
| | - W Xie
- Purdue University, West Lafayette, Indiana 47907, USA
| | - K Xin
- Rice University, Houston, Texas 77251, USA
| | - N Xu
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - Z Xu
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Q H Xu
- Shandong University, Jinan, Shandong 250100, China
| | - Y F Xu
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - H Xu
- Institute of Modern Physics, Lanzhou 730000, China
| | - Q Yang
- University of Science and Technology of China, Hefei 230026, China
| | - Y Yang
- Central China Normal University (HZNU), Wuhan 430079, China
| | - Y Yang
- Institute of Modern Physics, Lanzhou 730000, China
| | - S Yang
- University of Science and Technology of China, Hefei 230026, China
| | - C Yang
- University of Science and Technology of China, Hefei 230026, China
| | - Z Ye
- University of Illinois at Chicago, Chicago, Illinois 60607, USA
| | - P Yepes
- Rice University, Houston, Texas 77251, USA
| | - L Yi
- Yale University, New Haven, Connecticut 06520, USA
| | - K Yip
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - I-K Yoo
- Pusan National University, Pusan 609735, Republic of Korea
| | - N Yu
- Central China Normal University (HZNU), Wuhan 430079, China
| | - H Zbroszczyk
- Warsaw University of Technology, Warsaw 00-661, Poland
| | - W Zha
- University of Science and Technology of China, Hefei 230026, China
| | - Z Zhang
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - Y Zhang
- University of Science and Technology of China, Hefei 230026, China
| | - J B Zhang
- Central China Normal University (HZNU), Wuhan 430079, China
| | - J Zhang
- Shandong University, Jinan, Shandong 250100, China
| | - S Zhang
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - J Zhang
- Institute of Modern Physics, Lanzhou 730000, China
| | - X P Zhang
- Tsinghua University, Beijing 100084, China
| | - J Zhao
- Central China Normal University (HZNU), Wuhan 430079, China
| | - C Zhong
- Shanghai Institute of Applied Physics, Shanghai 201800, China
| | - L Zhou
- University of Science and Technology of China, Hefei 230026, China
| | - X Zhu
- Tsinghua University, Beijing 100084, China
| | - Y Zoulkarneeva
- Joint Institute for Nuclear Research, Dubna 141 980, Russia
| | - M Zyzak
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| |
Collapse
|
50
|
Li L, Peterson A, Soos T, Arendt C, Jones C. Redirection of Human CD4+ T Cell Responses with the Toll-like Receptor 4 (TLR4) Agonist Glucopyranosyl Lipid a (GLA). J Allergy Clin Immunol 2016. [DOI: 10.1016/j.jaci.2015.12.656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|